Public
Citizen, a research-based advocacy group representing more than 225,000 members and supporters nationwide, hereby petitions
the Food and Drug Administration (FDA), pursuant to the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 352, and 21 C.F.R.
§§ 10.30 and 201.56, to immediately add black box warnings and other safety information concerning several severe risks
to the product labels of all proton pump inhibitors (PPIs) presently on the market in the United States (U.S.) (Nexium,
Dexilant, Prilosec, Zegerid, Prevacid, Protonix, Aciphex, Vimovo, Prilosec OTC, Zegerid OTC, Prevacid 24-Hr, and all generic
counterparts). In addition, the serious nature of so many of these adverse reactions also mandates the requirement for FDA-approved
patient Medication Guides, none of which exist now, for all of these drugs.
For
the past 20 years, PPIs have become increasingly popular, partly because of their ability to relieve acid-related symptoms,
and are now one of the most widely used classes of drugs in the U.S., with 119 million prescriptions dispensed in 2009.1 Some of the approved uses for prescription PPIs are treatment
of gastroesophageal reflux disease (GERD), gastric ulcers and erosive esophagitis, and upper-gastrointestinal (GI) bleeding
prophylaxis with nonsteroidal anti-inflammatory drug (NSAID) use. However, PPIs are often prescribed outside of their approved
uses, for purposes such as stress ulcer prophylaxis in noncritical hospitalized patients2
and long-term treatment of conditions such as GERD past the approved time frame.3 It has been estimated that up to two-thirds of all people
on PPIs do not have a verified indication for the drug.4 In addition, even in many people with presumed GERD on PPI therapy, less intense acid-suppressive therapies are effective
in relieving symptoms,5 and in other cases, the
medical problem does not even involve acid reflux.6
Compounding
the problem of massive inappropriate use, recent evidence has documented several serious new safety problems with long-term
PPI use. For some of these risks, current FDA-approved PPI labels do not mention the adverse effect at all, including the
potential for developing dependence on the drugs, which results in rebound hypersecretion of stomach acid and recurrence of
symptoms after stopping PPI use. For other risks, even if mentioned, the label does not adequately explain or emphasize them.
There are currently no black box warnings in the label of any PPI.
This
petition outlines the current state of evidence of the risks involved with short- and long-term use of PPIs and asks that
the FDA make prescribers and consumers aware of these risks through the following labeling changes.
We
petition the FDA to require the inclusion of black box warnings identifying the following risks for all prescription PPIs
(and equivalent, prominent warnings for over-the-counter [OTC] PPIs):
-
Rebound acid hypersecretion risk: This is a form of dependence on PPIs that can be seen after as little as four weeks
of use. Patients and providers need to be made aware of the possibility of dependence on PPIs and alerted not to take or prescribe
PPIs beyond indicated uses and time frames. (Currently, this serious adverse effect is entirely missing from all PPI labels.)
-
Fracture risk: Long-term and multiple daily-dose PPI therapy has been associated with an increased risk for osteoporosis-related
fractures of the hip, wrist, or spine. Due to its potential severity, this adverse effect also needs to be placed in a black
box warning on all prescription PPIs and in an equivalent, prominent warning on OTC PPIs, in addition to its current place
in the ―Highlights‖ section of the prescription label.
-
Infection risk: An increased likelihood of serious infections, such as C. difficile-caused diarrhea and community-acquired
pneumonia has been seen with both short- and long-term PPI use. Pneumonia risk is currently entirely missing from all PPI
labels, while information on C. difficile infections — although attributed to all PPIs in the label —
is only present on three (Nexium, Prilosec, and Vimovo). Given the potentially fatal nature of these two conditions, particularly
in elderly and other vulnerable populations, information about both conditions needs to be placed in a black box warning.
-
Magnesium deficiency risk: Information on the risk of severe magnesium deficiency with long-term PPI use needs to be
placed as a black box warning due to its potentially fatal course. This adverse effect is particularly concerning, given the
possibility of concomitant use with many medications that prolong the QTc interval on an electrocardiogram, which in the presence
of low magnesium would increase the likelihood of life-threatening heart rhythm disruptions, or arrhythmias. (The FDA has
recently placed this information in the ―Highlights‖ section of all prescription — but not OTC — PPI
labels but has decided not to insert a black box warning.)
In
addition to the black box warnings, we petition the FDA to require the following label changes for all PPIs:
-
Drug-drug interactions: Taking PPIs may reduce the effectiveness of the heart-protective drug clopidogrel, leading
to an increased rate of serious cardiovascular adverse events, such
as a heart attack. Some PPIs (e.g., omeprazole) have been shown to have a higher likelihood of interaction than others (e.g.,
pantoprazole); however, several PPIs have been implicated. Although a version of this warning is already on the omeprazole
label, mention should be made in the ―Highlights‖ section of all PPIs that the potential for a classwide
interaction cannot be ruled out at this time.
Appropriate
risk information on a potential interaction with at least two other medications used to treat serious conditions — methotrexate
and mycophenolate mofetil — needs to be listed in the label.
-
Vitamin B12 deficiency: The available evidence on the potential for vitamin B12 deficiency with long-term PPI use needs
to be placed in the appropriate section of the label. Although the label states that this can occur with ―any acid-suppressing
medication,‖ the warning has only been placed on the label for one PPI (Dexilant).
-
Acute interstitial nephritis: Information regarding the potential for drug-induced acute interstitial nephritis, seen
in at least 60 case reports, should be included in the appropriate section. There is currently no detailed risk information
on any PPI for this adverse effect.
-
GERD-treatment length consistency: All PPIs approved for the treatment of GERD should have specific recommendations
for length of treatment in the ―Indications‖ section of the label.
Finally,
we urge the FDA to:
-
Require the distribution of FDA-approved Medication Guides for patients — containing these adverse effect warnings and
describing alternatives to PPI use for all patients — to be dispensed when prescriptions are filled.
-
Ask the sponsors of all PPI medications to send a ―Dear Doctor‖ letter alerting physicians to these adverse effects
and to include information on appropriate prescribing of PPIs in inpatient and outpatient settings.
It
is critical that these potentially dangerous adverse effects be made known to the public since they pose a serious threat
to the general well-being of PPI users. The added risk information, and provider and patient awareness of appropriate PPI
use, should help to limit the massive amount of needless overprescribing.
I.
STATEMENT OF GROUNDS
A.
Basic physiology in the stomach: gastrin, gastric acid release, and inhibition7
The
production and release of gastric acid into the stomach is a crucial component of digestive function in humans, responsible
for breaking down many foods that enter the stomach, thus making absorption possible further down the GI tract. Parietal cells
carry out the final step in the physiologic pathway responsible for acid secretion in the stomach. Two hormones, gastrin and
somatostatin, are primarily responsible for the regulation of acid secretion. Gastrin is a hormone stored by G cells in the
stomach that is responsible for initiating gastric acid release by acting on enterochromaffin-like (ECL) cells and, to a lesser
extent, parietal cells. In the predominant pathway, gastrin stimulates histamine release from ECL cells. This histamine then
binds to parietal cell histamine-2 (H2) receptors, causing the parietal cells to secrete gastric acid. Somatostatin, a hormone
released by oxyntic D cells in the stomach, is the main inhibitor of histamine release from ECL cells and also inhibits the
release of gastrin from G cells.
Negative
feedback loops, primarily involving the opposing actions of gastrin and somatostatin, keep the level of acidity in the stomach
within a certain range. When gastric acidity increases (pH decrease), somatostatin levels rise to inhibit gastrin secretion
and ECL cell histamine release, thus making the stomach more alkaline. Conversely, when stomach acidity decreases (pH increase),
somatostatin levels decrease, causing gastrin levels to rise, making the stomach more acidic. Thus, acid release in the stomach
relies on a delicate hormonal balance involving gastrin and somatostatin, an interaction that is described as ―…
a cornerstone in the physiology of meal-stimulated acid secretion.‖8 Any disruption to this balance, as clearly seen with PPIs,
may potentially lead to long-term complications.
B.
Hypergastrinemia and symptomatic rebound acid hypersecretion: a form of dependence on PPIs
There
is increasing evidence that after using PPIs for a month or more — whether they are being used for approved indications
or by otherwise healthy people — upon withdrawal of PPIs, there is a rebound hypersecretion of acid, accompanied by
symptoms, as the drug-increased, acid-secreting activity in the stomach is no longer being suppressed by the PPIs. This creates
a long-term dependence on these drugs. Given the millions of people on PPIs for mild and often vague symptoms, a large number
of people are being exposed to a dependence-inducing substance without their knowledge. A recent editorial about PPI rebound
acid hypersecretion (RAHS) stated: “The current finding that these drugs induce symptoms means that such liberal
[mis-] prescribing is likely to be creating the disease the drugs are designed to treat and causing patients with no previous
need for such therapy to require intermittent or long-term treatment.”9
The
RAHS phenomenon is thought to be caused by the indirect PPI-induced effects on gastrin.10 Treatment with acid-suppressive agents significantly
decreases the amount of acid in the stomach. As a result, gastrin is subsequently produced at a much higher rate in order
to compensate for the acid deficiency in the stomach. These high levels of gastrin in turn stimulate the growth and proliferation
of ECL cells, which cannot stimulate acid production because of inhibition of this function in parietal cells by PPIs. After
the discontinuation of the acid-suppressant, these ECL cells, now increased in number as a result of PPI therapy, appear to
stimulate parietal cells to release a greater amount of acid than prior to therapy.
Previously,
it has been shown that this phenomenon occurs with another class of acid-suppressing agents, H2-receptor antagonists (H2As).11,12,13 However, two
studies, including one randomized controlled trial, of patients on H2A therapy showed much shorter durations of RAHS (median
of 2 days in one, and less than 10 days in another) than found in studies of RAHS with PPI discontinuation,14,15 while another study showed only
a nocturnal RAHS effect after H2A therapy, with daytime acid output unaffected.16 This milder RAHS effect seen after H2A therapy is likely
due to the fact that H2As are less potent inhibitors of gastric acid release than PPIs, and that tolerance to H2As, but not
to PPIs, develops in many patients, further diminishing the acid-suppressing ability of H2As.17
The
first study demonstrating RAHS after discontinuation of PPI therapy was by Waldum et al in 1996. The authors found that 14
days after discontinuation of a three-month course of omeprazole in patients with reflux esophagitis, the median stimulated
gastric acid secretory capacity was increased by 50% over the pretreatment baseline.18 Other reseachers later found that this increased
acid-secreting capacity persists for two months after cessation of PPIs.19
However,
the early studies assessing RAHS in subjects on acid-suppressing therapy were inconsistent, lacking uniformity in their design
and their results. One common trend in these studies, however, was that the therapies with a shorter duration often failed
to show the RAHS phenomenon,20,21,22,23 and conversely, some of the trials with longer therapies were able to show RAHS.24,25,26 Thus, these early
studies demonstrated that duration of therapy has a clear association with the development of RAHS — a key finding suggesting
causality.
Potential
for PPI dependence in healthy volunteers: RAHS not just a recurrence of previous symptoms
The
resumption of symptoms after discontinuation of PPI therapy might simply indicate that the pretreatment symptoms had returned.
However, two recent randomized, controlled trials have shown that even healthy volunteers have the potential for long-term
dependence on these drugs. In 2009, Reimer et al demonstrated that symptomatic RAHS could occur even in previously healthy
people.27 In
a randomized, double-blind, placebo-controlled trial of 120 healthy volunteers, subjects were randomized to either 12 weeks
of placebo or eight weeks of once-daily esomeprazole (40 milligrams [mg]), followed by four weeks of a placebo. In the weeks
after stopping treatment, almost three times as many subjects who had received esomeprazole for eight weeks experienced relevant
acid-related symptoms compared to those who had received a placebo. In addition, almost five times as many subjects who had
received esomeprazole needed ―escape medications‖ to treat these symptoms as those in the placebo group. Gastrin
levels for the esomeprazole group significantly increased after treatment started and were found to have a strong correlation
with acid-related symptoms in weeks eight and 10 for this group. Chromogranin A (CgA) levels, reflective of ECL cell hyperplasia,
rose for the esomeprazole group shortly after therapy began and remained elevated compared with baseline through the end of
the study at week 12.
The
results of this study suggest that RAHS is not a recurrence of previous symptoms but an effect of the PPI itself creating
the symptoms it was originally intended to treat. The authors concluded, ―These results justify the speculation that
PPI dependency could be one of the explanations for the rapidly and continuously increasing use of PPIs.‖28
The
trial is in agreement with earlier studies, mentioned above, that attempted to assess the effects of long-term PPI use. It
must be noted that the eight-week period it took to develop RAHS is within the FDA-approved time period for GERD treatment
with most PPIs. This eight-week time frame is also consistent with the likelihood that ECL cell hyperplasia is triggering
RAHS. Waldum et al, the original authors documenting RAHS with PPI therapy cessation, elaborated on the ECL cell hyperplasia
mechanism, mentioning that the duration of RAHS (two to three months in some cases) correlates well with the relatively short
life span of the ECL cell.29 ECL cell hyperplasia and increased ECL cell volume have been confirmed in patients treated with omeprazole
for periods of up to four or five years.30 Other studies have shown elevated levels of mucosal histamine (a product of ECL cells) after
PPI therapy.31,32 These results all strengthen the likelihood that gastrin-induced ECL hyperplasia resulting from PPI therapy is the
cause of RAHS.
The
majority of earlier studies ignored whether their subjects were infected with Helicobacter pylori. This is important
because other studies have demonstrated that there are differences in the acid-secreting abilities of H. pylori-positive
and -negative individuals, as H. pylori-positive individuals may be less susceptible to the RAHS phenomenon than H.
pylori-negative subjects.33 Indeed, one limitation of the Reimer et al study was that a higher proportion of placebo subjects were
positive for H. pylori (13% vs. 2% in the treatment group), possibly leading to a masking of symptoms in this group.
However, as there was no difference in symptoms at baseline between the two groups, this difference likely did not affect
the posttreatment outcome.
A
more recent randomized, double-blind, placebo-controlled study by Niklasson et al addressed this potential confounder, while
confirming the presence of RAHS in otherwise healthy subjects exposed to PPIs.34 The trial differed from the Reimer et al study in that it
used only H. pylori-negative individuals in a briefer, four-week, treatment period. The results, however, were similar
to that study. The PPI group had significantly higher rates of dyspeptic symptoms in the first (44% vs. 9% in placebo group)
and second (24% vs. 0% in placebo group) week after withdrawal. CgA and gastrin levels were significantly higher in the PPI-treated
group than in the placebo group by the last week of treatment. This study demonstrated that significant rebound symptoms can
develop with treatment periods as short as four weeks.
The
theory of PPI dependence is further supported by empirical evidence from studies showing how difficult it is for patients
initiated on PPIs to stop using their medication. In a randomized, double-blind trial in which subjects attempted to discontinue
or taper long-term use, only 27% of patients were able to successfully remain off PPI therapy one year after the initial attempt
to discontinue therapy.35 All other patients had recurring symptoms or needed to resume PPI therapy. Patients with higher baseline serum gastrin
levels and patients with GERD were more prone to resume PPI therapy than were others. As participants had been previously
made aware that it would be a PPI withdrawal trial, it is unlikely that those with more severe symptoms would have offered
to participate. Thus, this study may have underestimated the difficulty of discontinuing PPI treatment.
An
editorial by McColl and Gillen accompanying the Reimer et al. study expressed concern over the risk posed by PPIs in causing
the symptoms they purport to treat.36 It is clear that many people are initiating PPI therapy and staying on it for months, or even years, beyond
its indicated time frame.37 A clear reason for this possible dependence stems from the development of RAHS. As McColl and Gillen stated
in their editorial, ―Now that rebound acid secretion has been demonstrated to induce symptoms, we are probably obliged
to inform them about rebound acid hypersecretion and its potential effects.‖38 A black box warning and a patient Medication Guide are therefore
necessary to warn about this well-documented danger of PPI dependence and the hazards therein.
C.
Increased risk of fractures
On
May 25, 2010, the FDA announced that it was requiring a change in prescription and over-the-counter labeling of PPIs to include
safety information about the risk of hip, spine, and wrist fractures in response to a review of seven recent epidemiological
studies (six of which associated PPI use with fracture risk).39 Accordingly, a few months later, on September 3, 2010, the FDA approved a new
label change for PPIs to include the risk of hip, wrist, and spine fracture from long-term and multiple daily-dose PPI therapy
in patients with osteoporosis, but the agency has not required a black box warning.
The
primary trial to influence this change came from an epidemiological study by Gray et al. that included women enrolled in the
Women‘s Health Initiative and was published in May 2010.40 The study involved 161,806 postmenopausal women, between the ages of 50 and 79,
without a previous history of hip fracture. Outcomes measured were self-reported fracture (adjudicated) and bone mineral density
(BMD) (baseline and three-year change). Results showed a significant increase in clinical spine (HR 1.47), forearm/wrist (HR
1.26) and total fracture (HR 1.25) risk, but not in hip fracture risk (HR 1.00), for PPI users. This translates to 47%, 26%,
and 25% increased risks for clinical spine, forearm/wrist, and total fracture, respectively, for postmenopausal women on PPI
therapy compared to nonusers. Although an increase in hip fractures was not noted, PPI use was associated with reduced BMD
in the hip (p=0.05). In addition, although a dose-response analysis was unable to be conducted, and there was no association
between duration of use and fracture risk, the results from this large study are fairly robust due to its large sample size
and the amount of information available in patient records, which allowed for adjustment for numerous confounders.
Multiple
studies have found increased fracture risks at higher PPI doses and with longer treatment durations, strengthening the proposed
causal relationship. In a 2006 case-control study, Yang et al found an adjusted odds ratio of 1.44 for increased risk of hip
fracture with PPI use for more than one year in adults over the age of 50.41 Both longer duration and higher dose of PPI therapy were
associated with a significant increase in the risk for hip fracture. In a recent review, PPI use of four years or more was
associated with a significantly higher likelihood (OR 1.62-4.55) of hip fracture, with no effect seen with less than four
years of use.42 Finally,
in a recent review of 14 studies comprising one million patients, an increased overall risk of fractures was found with one
year of continuous PPI use, with both increased dose and duration linked with higher risk in a subgroup analysis.43
The
precise mechanism for the increased fracture risk seen with PPI use is as yet unclear. Some speculate that decreased acidity
in the stomach leads to calcium malabsorption and decreased bone mineral density, although study results have been mixed on
this proposed mechanism.44,45,46,47 Magnesium deficiency linked to long-term PPI use (see discussion below) could also contribute to fracture
risk either independently48 or through alteration of calcium metabolism.49 Others have proposed that PPIs may have a direct effect on bone resorption, with
a hypothesis that PPI action on vacuolar ATPases might limit the ability to repair microfractures and increase overall fracture
risk without lowering BMD.50 Another possibility is that acid-suppressive interference in vitamin B12 absorption could lead to hyperhomocysteinemia,
a predictive factor for hip fracture.51
One
additional consideration is the potential for PPIs to attenuate the beneficial effect of medications, such as bisphosphonates,
on preventing fractures. A recent Danish cohort study of 38,088 men and women on alendronate found that concomitant PPI therapy,
in a dose-dependent manner, reduced the benefit of the medication on hip fracture risk.52 Thus, in addition to increasing the risk of hip
fracture, PPIs may also interfere with medications intended to decrease the risk of osteoporosis-related fractures.
Though
the mechanism of PPI-associated fractures still needs to be further evaluated, and the role of confounding variables is still
unclear, what is clear is that there is sufficient evidence associating PPI use with increased fracture risk. The FDA has
acknowledged this association and acted accordingly by placing a warning of this risk in the label of all PPIs. However, this
risk, particularly in the osteoporotic elderly population, carries with it the potential for significant morbidity and, in
some cases, mortality resulting from such fracture events. Therefore, a black box warning — in addition to the current
label change — is necessary to alert all prescription PPI users of this potentially fatal adverse event.
It
should be emphasized that a prominent warning must also be restored on all OTC PPIs. The FDA recently reversed its original
position and removed the existing warning on fracture risk from all OTC PPI labels, reasoning that these medications are approved
only at lower doses and for short-term (14-day) courses.53 However, in its updated Drug Safety Communication, the FDA acknowledges that
―consumers … may take these products for periods of time that exceed the directions on the OTC label.‖54 In addition, given
that OTC PPIs are considerably less expensive than their prescription counterparts,55 patients (or their doctors) may substitute OTC
for prescription PPIs for long-term therapy. Therefore, the decision to remove this warning, while simultaneously conceding
that patients may take these medications for long-term use, is a dangerous move by the FDA and ignores the need to inform
those consumers of a potentially fatal adverse effect. Information on the risk for fractures needs to be reinstated on all
OTC PPIs.
D.
Development of GI infections and pneumonia
The
presence of normal amounts of gastric acid is important for preventing gastrointestinal bacterial colonization. It is therefore
biologically plausible that the use of PPIs and the subsequent reduction in gastric acidity would increase the likelihood
for bacteria to thrive in the GI tract. Indeed, in several studies, including one randomized, controlled trial, patients on
long-term PPI therapy have been shown to develop significantly higher rates of bacterial overgrowth in the stomach and small
intestine, with longer duration of use and higher gastric pH both linked to higher rates of overgrowth.56,57,58 Many patients in the hospital
setting who are already susceptible to infections are frequently prescribed PPIs for unapproved indications, such as stress
ulcer prophylaxis, which could make them even more vulnerable to illness.59 PPI use and Clostridium difficile infection
Clostridium
difficile infection (CDI) has been clearly tied to PPI use. This bacterial infection
is commonly seen in hospitals, and the toxin produced by the bacteria is associated with the development of severe diarrhea.
It has been shown that more acidic gastric juice is better at killing this bacteria and neutralizing its toxin than less acidic
gastric juice.60 Therefore, lowering the acidity
(increasing the pH) with PPI therapy could allow the bacteria to survive better and its toxin to remain active for a longer
time.
Although
there are numerous risk factors for CDI, results from recent trials suggest a clear association with PPI use. A five-year
cohort study from Jayatilaka et al found a correlation between increased PPI use and the increase in annual incidence of CDI-associated
diarrhea in an urban medical center, from 5.08 to 8.42 cases per 1,000 admissions (rs=1.0; p=0.017).61 In
the last year of the study, a case-control analysis was performed comparing PPI and H2A use with the development of CDI. PPI
therapy showed the highest risk if it was used before or upon admission (OR 2.75), and there was still a significantly high
risk if initiated only upon admission (OR 1.88), compared to non-use. The weaker H2A therapy did not show increased risk.
It is possible that, because the less potent H2As do not increase gastric pH as much as PPIs do, H2As do not allow C. difficile
to flourish. All results were adjusted for antibiotic use, a potential confounder and known risk factor for CDI.
Other
studies have come to similar conclusions about PPIs and CDI risk. Howell et al performed a comparable five-year cohort study
that associated increased dosages of acid-suppressive therapy with an increased likelihood for developing nosocomial CDI.62 Daily PPI therapy increased risk by 74%, and more frequent
PPI use increased risk by 136% compared to no acid-suppressing therapy, thus demonstrating a dose-response relationship. PPI
use has also been linked to greater severity of the illness. In a retrospective study of 627 patients with CDI and colitis
(CDIC) in one hospital, there was a significant increase in adjusted risk (OR 1.65, 95% CI 1.05-2.61) of severe CDIC for patients
who received a PPI within 30 days of admission compared to those who had not. Those on PPIs and concomitant antibiotics were
at even greater risk of severe CDIC (OR 2.51, 95% CI 1.73-3.66) compared to those who received neither treatment.63 Another study in predominantly older men at a Veterans Affairs
hospital showed that patients placed on PPI therapy within 14 days after an initial episode of CDI were at a higher risk for
recurrent CDI than patients not on therapy.64
PPI
use and community-acquired pneumonia
PPI
use has also been linked to higher risk of developing community-acquired pneumonia (CAP). Eom et al outlined several possible
mechanisms by which PPI use may lead to CAP.65 As
described above, PPIs induce bacterial overgrowth in the upper (GI)tract. These infected secretions may be aspirated, particularly
in older patients, leading to pneumonia. Alternatively, PPIs may inhibit the function of the hydrogen-potassium adenosine
triphosphatase enzymes found in the respiratory tract, thereby altering the pH of the secretions, leading to bacterial growth
in the respiratory tract itself and pneumonia development. A 2004 cohort study of 364,683 patients in general practitioner offices by Laheij
et al calculated an 89% increased risk of developing CAP in PPI users compared to those who had stopped using PPIs.66 A dose-response effect
was seen in PPI users, with those on the equivalent (adjusted odds ratio [aOR] 1.94; 95% CI 1.41, 2.68) or more than the defined
daily dose (DDD) (aOR 2.28; 95% CI 1.26, 4.10) at increased risk for CAP relative to past users of acid suppressants, while
those on low-dose PPIs (less than the DDD) were not at increased risk (aOR 1.23; 95% CI 0.78, 1.93). As is commonly the case,
those with pneumonia (cases) had more comorbidities at baseline than those without pneumonia (controls). However, these were
adjusted for in the risk calculations. In addition, current PPI users were compared to past PPI users, thus diminishing the
likelihood that the increased risk of CAP was due to the fact that PPI users are often sicker than the general population.
A subsequent, larger study reached a similar conclusion, with an increased risk of CAP seen only in current PPI users (aOR
1.5; 95% CI 1.3, 1.7) and not in recent past users (aOR 1.2; 95% CI 0.9, 1.6). Although in the latter study, a dose-response
relationship was not found.67
Although
a meta-analysis performed by Sultan et al did not find a statistically significant increase in overall risk of respiratory
infections due to PPI use, there was an absolute increase in incidence.68
Cumulative respiratory infections developed in 4.3% and 3.4% of
the treatment and placebo groups, respectively (total OR 1.42, 95% CI 0.86, 2.35 for the treatment group). Only one of the
seven included trials showed a significant association between PPI therapy and respiratory infection, with high-dose esomeprazole
(40 mg) associated with respiratory infection in 4.3% of patients, compared to 0% in the placebo group.69
It
would not be surprising to see this increased risk in certain kinds of patients more often than others. Older patients who
have been admitted to the hospital for CAP are more likely to have recurrence if they are currently on PPI therapy. As calculated
by Eurich et al, adjusted odds were increased by 83% for older patients (≥ 65 years of age) newly prescribed PPIs after
their last hospital discharge for CAP.70 Rodriguez et al showed that the risk was only increased with short-term use (between one month
and 12 months after starting PPI treatment) and when a PPI was used for dyspepsia or peptic ulcer disease.71 In a more recent meta-analysis of
31 studies by Eom et al, there was an association between PPI use and the occurrence of community-acquired pneumonia in a
subgroup analysis (aOR 1.34, 95% CI 1.14, 1.57). A dose-response relationship was observed, with higher PPI dose associated
with increased pneumonia risk. 72
These
findings point to a clear association between PPI use and potentially severe infections such as CDI and CAP. The significant
morbidity and mortality that often results from these two conditions, particularly in elderly patients and other vulnerable
populations, need to be considered in any analysis of harms and benefits of PPI therapy. Therefore, a black box warning and
a patient Medication Guide are necessary to warn about the risk of developing these dangerous infections.
E.
Magnesium deficiency
Another
serious problem associated with long-term PPI use, and described more recently in multiple case series (and in a recent review),
is severe hypomagnesemia.73 Based on an extensive review of the literature and FDA Adverse Event Reporting System (AERS) database,
the FDA recently released a Drug Safety Communication confirming that magnesium deficiency has been linked to long-term (greater
than one year) PPI use.74 The agency recommended obtaining baseline magnesium levels in all patients prior to initiation of long-term PPI therapy,
and in patients on digoxin, diuretics, or medications that also may cause hypomagnesemia.
Since
the 2006 publication by Epstein et al75 of two case reports detailing hypomagnesemia and hypoparathyroidism in PPI-treated patients,
the number of hypomagnesemia cases has increased substantially. Although the exact mechanism is unknown, it is suspected that
either a decrease in absorption or an increase in secretion of magnesium in the small intestine is responsible.76 In severe cases of
hypomagnesemia reported thus far in a recent review of all cases reported in the literature through July 2010 (28 patients;
all over 50 years old), the factor most suggestive of a causal relationship has been evidence of resolution in all cases only
after withdrawal of the PPI.77 As the authors of this review point out, levels from 0.05 to 0.35 millimole per liter (mmol/L; less than
half the lower limit of the normal range of 0.8-1.2 mmol/L) have been recorded in patients presenting symptoms of seizure,
tetany, and other serious conditions. One additional consideration is the ability of long-term, profound hypomagnesemia to
suppress parathyroid hormone secretion, thus leading to hypocalcemia in some cases.78,79 Indeed, in the review above, those with severe
hypomagnesemia commonly exhibited hypocalcemia.80 This is particularly relevant to the association between fractures and PPI use, in which impaired
calcium absorption is a possible contributor.
Although
no large clinical trials have been conducted concerning the potential effect of PPIs on magnesium, the biological plausibility
and available case series do exhibit some criteria (e.g., positive rechallenge and dechallenge) that suggest causality, as
pointed out by the FDA‘s recent communication.81
The
FDA has taken a good first step in its move to include this risk information under the Highlights section of all prescription
PPIs. However, since magnesium levels as low as those seen in the published case series can cause fatal cardiac arrhythmias
and other life-threatening complications, patients and providers need to be alerted of this possibility through a more prominent
Black Box Warning. Furthermore, as stated above for fracture risk, a similiar warning should be placed on OTC PPIs as the
FDA has acknowledged that patients may take these medications for longer than the indicated time period. In addition, patients
taking OTC PPIs long-term may already be on magnesium-reducing medications, such as diuretics, and, in the absence of appropriate
supervision by a medical professional, will incur an even greater risk. Thus, these and other patients on OTC PPI therapy
need to be warned of this potentially life-threatening side effect.
F.
Drug-drug interactions and other adverse reactions
PPIs
have a wide array of potential interactions with normal metabolic systems and other drugs. Many of these interactions are
caused by the significantly increased gastric pH induced by PPIs, as well as interference with cytochrome pathways responsible
for the metabolism of certain drugs.
Inhibition
of beneficial clopidogrel effect One drug whose benefit may be significantly diminished by the concomitant use of PPIs is clopidogrel. Clopidogrel
inhibits platelet aggregation and is indicated for the prevention of heart attacks and other cardiovascular events in patients
with coronary artery disease (CAD). It is commonly combined in therapy with PPIs because clopidogrel also increases the risk
of GI bleeding. It has been established that adding a PPI to a patient‘s drug regimen diminishes the risk of GI bleeding
with anticoagulation.82,83 A recent consensus statement from the American College of Gastroenterology (ACG), the American College of Cardiology
Foundation (ACCF), and the American Heart Association (AHA) recommended the administration of a PPI to patients with CAD on
antiplatelet therapy who have a history of, or multiple risk factors for, an upper-GI bleed.84
However,
there have recently been a number of studies that have found that the anti-coagulant effect of clopidogrel may be diminished
by concomitant administration of a PPI. Both PPIs and clopidogrel interact via the same metabolic (CYP2C19 cytochrome) pathway.
It is currently thought that PPIs may competitively inhibit the anti-clotting action of clopidogrel by blocking the conversion
of clopidogrel, a pro-drug, to its active metabolite. The FDA has also concluded that concomitant use of PPIs during clopidogrel
therapy poses potential health risks. On November 17, 2009, the FDA proposed changes to the labeling for clopidogrel to note
the dangers of interaction with omeprazole, recommending that other drugs that reduce stomach acid — namely, H2As —
might be safer.85
Although
some studies have shown a significant effect of PPIs on the antiplatelet effect of clopidogrel,86 others have not.87 Furthermore, it was initially unclear
whether any such effect on the antiplatelet activity on clopidogrel has any clinical significance. In an attempt to answer
this question, there have been several observational studies and one randomized, controlled trial designed to assess the potential
interaction between clopidogrel and PPIs.
A
2010 cohort study by Stockl et al analyzed the risk of rehospitalization for myocardial infarction (MI) and coronary stent
replacement in patients on the combined therapy. Using both clopidogrel and PPI increased the risk of rehospitalization for
MI by 93% and the risk of rehospitalization for MI or coronary stent placement by 64%, compared with patients using clopidogrel
alone. However, a potential confounding factor was that those on both clopidogrel and PPI had a higher rate of baseline comorbidities
than those only on clopidogrel, a common limitation to many of the observational studies examining the interaction between
the two drugs.88 The interaction between clopidogrel and PPIs has been controversial due to this question of confounding, namely that
those on PPIs tend to be sicker and at higher risk for adverse outcomes. Although some studies have suggested this confounding
effect,89,90 large
studies have consistently shown a significant interaction between PPIs and clopidogrel even after controlling for all known
confounders.91,92
To
help clarify the role of confounding variables, a large, randomized, controlled trial (the COGENT trial) was recently undertaken
to investigate whether PPI co-administration caused higher rates of adverse events in patients on clopidogrel, in addition
to aspirin.93 Patients
on a combination of clopidogrel and omeprazole did not show higher rates of a composite end point of death from several cardiovascular
adverse events than patients getting clopidogrel alone. However, the study was
terminated early due to loss of funding, thus limiting its detection power. In addition, the patient population and clinical
end points were not consistent with the earlier studies that formed the basis for the FDA‘s determination that there
was a significant interaction between omeprazole and clopidogrel.94
Genetic
factors also may play a role in the effectiveness of clopidogrel therapy. Individuals with two ―loss-of-function‖
alleles in the gene for the CYP2C19 enzyme responsible for activation of clopidogrel are considered poor metabolizers of the
drug. Certain subpopulations, such as East Asians, with a higher prevalence of poor metabolizers95 are particularly vulnerable to the
inhibitory effects of PPIs. Huang et al showed significantly higher rehospitalization for CAD and overall mortality (but not
revascularization) in East Asians using both drugs, as opposed to those solely on clopidogrel after percutaneous coronary
intervention.96 Poor
metabolizers already experience reduced efficacy of clopidogrel due to their diminished ability to convert the inactive (swallowed)
form of the drug to the active form. Therefore, any further reduction in clopidogrel‘s action by PPIs could be particularly
dangerous in this population.
Interaction
with clopidogrel is possibly classwide
Different
drugs within the PPI class have been studied to assess whether the interaction with clopidogrel is confined only to certain
PPIs. The FDA has acknowledged the presence of an interaction with the omeprazole 80 mg/day dose and placed a warning on the
drug‘s label to reflect this concern.97 It has been suggested that other PPIs (e.g., pantoprazole) may not share the same interaction
potential with clopidogrel, as they do not have the same inhibitory effect on the metabolic (CYP2C19) pathways in question.
Indeed, a recent randomized, crossover trial involving patients on dual antiplatelet therapy following an MI suggested that
the interaction was limited to omeprazole.98
However,
several studies have suggested a significant interaction between clopidogrel and other PPIs, including pantoprazole.99,100,101 A randomized
open-label trial involving 87 patients found that both omeprazole and rabeprazole lead to clopidogrel nonresponsiveness as
measured by maximal platelet aggregation (MPA), and that the rate of nonresponsiveness was not significantly different between
the two PPIs.102 Kreutz et al, in a retrospective cohort study of 16,990 patients on clopidogrel who had undergone coronary artery
stent placement, found that concomitant administration of omeprazole, esomeprazole, lansoprazole, or pantoprazole all raised
the adjusted risk of cardiovascular events compared to clopidogrel alone over a one-year period.103
Thus,
although the existing evidence is limited at this time, there is a suggestion of a classwide interaction between PPIs and
clopidogrel. Therefore, patients need to be alerted to this possibility. Although the evidence on an interaction with high-dose
omeprazole is more definitive at this point, patients and providers alike need to be informed that it is still unclear whether
switching to another PPI while on clopidogrel is truly a safer option.
Other
drug-drug interactions
Through increasing gastric pH so profoundly,
PPIs have been shown in studies to alter the absorption of multiple medications. Indeed, as stated in the Nexium label, this
alteration of gastric pH has been implicated in interactions with several drugs (e.g., ketoconazole, iron salts, and digoxin).104 However, other medications
whose plasma levels may be altered by PPI-induced hypochlorhydria (decreased acid secretion) — or other mechanisms —
are not included in the label. Two such drugs whose levels in the blood may be affected by PPIs are listed below.
-
Mycophenolate Mofetil (Cellcept): Decreased Absorption, Decreased Blood Levels
One
potential interaction not listed in the labels of PPIs involves mycophenolate mofetil (MMF or Cellcept), an immunosuppressant
given to organ transplant recipients to stave off immunologic rejection of the transplanted organ. MMF is a pro-drug that
is converted to the active metabolite mycophenolic acid. Two pharmacokinetic studies have shown a significant effect of various
PPIs in reducing the plasma concentrations of the mycophenolic acid.105,106
Although a new, enteric-coated version of MMF did not show the same
interaction in a recent trial, this is a preliminary finding, and other results of a larger, currently planned study are pending.107 Any decrease in the
function of MMF could be serious, potentially resulting in transplant rejection.
-
Methotrexate (Folex, Trexall): Decreased Clearance, Increased Blood Levels
Methotrexate
is a drug whose clearance, rather than absorption, may be affected by concomitant PPI use. In a recent retrospective study
in France on patients undergoing treatment for certain malignancies, concomitant PPI use was found to be likely responsible
for delayed renal elimination of methotrexate, thereby increasing plasma concentrations of the drug and its associated side
effects.108 Of
39 treatment cycles where delayed elimination was found, 17 were attributed to PPI co-administration. Serious adverse events,
including acute renal failure, aplastic anemia, and tumor lysis syndrome, resulted from this delayed clearance. This study‘s
results confirmed those of a prior study of 76 cancer patients, where PPIs decreased methotrexate plasma clearance by 27%,
resulting in significantly increased plasma concentrations.109 In the French study, the authors concluded that, based on their evidence and
those of prior studies, ―… proton pump inhibitor administration should be discontinued during methotrexate treatment.‖110 Although the evidence
on an interaction between PPIs and methotrexate may still be limited, the potential consequences resulting from methotrexate
toxicity warrant the listing of appropriate risk information in all PPI labels.
Thus,
there are two medications whose plasma levels have been shown to be significantly altered by concomitant PPI use, but these
adverse interactions are not presently listed in the labels of PPIs. These medications, mycophenolate mofetil and methotrexate,
are both used to treat or prevent serious conditions, such as cancer and organ transplant rejection. Therefore, any interactions
related to these medications are concerning. Alerting health care providers to all possible interactions with PPIs through
a comprehensive listing — not a partial list (e.g., for drugs affected by alterations in gastric pH), as is the case
currently — of suspected medications is essential.
Vitamin
B12 deficiency
PPIs
can potentially affect the absorption and metabolism of many other substances. Anything that is dependent on gastric acid
for absorption and metabolism would plausibly be affected. While vitamin and mineral deficiencies related to PPI use have
not been shown consistently across all studies, overall, these may be important considerations in the elderly and other populations
vulnerable to malnutrition.
Vitamin
B12 (B12) is an essential nutrient that could be affected by PPI therapy. Pepsin, produced in the stomach, is needed to release
B12 from foods but must first be converted from pepsinogen, a process that is dependent on high gastric acidity. Studies have
not given consistent results on the effects of PPI use on B12 status,111,112,113
although longer duration of PPI use has been linked to lower B12
levels.114 A
case-control study in 2004 found that subjects with B12 deficiency were more likely to have taken acid suppressants than those
with normal B12 levels.115 A key finding was that this association did not hold for past users of acid suppressants, diminishing the likelihood
that an association was due to confounding. In addition, as B12 deficiency is a process that can take years to develop, no
association was found with short-term acid-suppressant use. This was confirmed in a cross-sectional study of 542 older adults
in long-term care facilities and outpatient clinics.116 Longer duration of PPI use was significantly associated with lower serum B12
levels. However, another cross-sectional study of 125 couples in the Netherlands did not confirm this association, with no
difference in serum B12 levels observed between long-term PPI users and their partners, or between long-term PPI users (≥
six years) and those on PPIs for shorter periods (three to five years).117
A
major limitation of this and other studies is their cross-sectional nature. Therefore, more robust observational or randomized
studies are needed to clarify the association between long-term PPI use and B12 deficiency. Until that time, the existing
evidence needs to be made available to patients and providers alike.
Acute
interstitial nephritis
A
systematic review published in 2007 examined all published case reports of acute interstitial nephritis (AIN) associated with
PPI therapy.118 Of
60 case reports included in the review, 44% did not involve exposure to any other medications that were known to cause AIN
or involved no other medication exposure at all. Four patients had a decrease in renal function after restarting the PPI,
suggesting positive rechallenge. The authors concluded that 21 of the 60 cases had a ―certain‖ or ―probable‖
relation to PPI use, with another 37 classified as ―possibl[y]‖ related. In addition, as AIN occurred with five
different PPIs (omeprazole, pantoprazole, esomeprazole, lansoprazole, and rabeprazole), the effect may be classwide.
The
majority of patients were elderly (mean age, 78 years), indicating that this age group may be particularly vulnerable to AIN
from chronic PPI use. Although there were no deaths due to acute renal failure, one-third of the subjects required corticosteroid
therapy, and three patients required dialysis, with one remaining on dialysis permanently. Thus, the potential for severe
sequelae following AIN possibly induced by PPI use necessitates proper alerting of patients and providers to this serious
adverse effect. More evidence is needed to firmly establish a cause-and-effect relationship, but until further studies are
undertaken, the existing evidence should be placed in the label.
G.
PPIs and the development of gastric cancer
Numerous
animal studies have shown that PPIs may be associated with the development of gastric carcinoids and carcinomas, two types
of stomach cancer. This is of particular concern in patients with the bacterial infection H. pylori, and the potential
connection is biologically plausible.
Gastric
cancers: carcinoma and carcinoid
Gastric
cancer is a varied disease entity, with several risk factors and pathophysiologic pathways. Two common subtypes are adenocarcinoma,
derived from glandular cells in the gastric mucosa, and carcinoid tumors, neuroendocrine neoplasms derived from ECL cells.
Gastric adenocarcinoma is by far the more common, and the more lethal,119,120
of the two and is known to be caused (in certain anatomic sites)
by H. pylori infection121 and other conditions that lead to atrophic gastritis, a chronic inflammatory state in the stomach that
predisposes to carcinoma development. Gastric carcinoid is a neuroendocrine tumor originating from ECL cells within the gastric
mucosa and is divided into three types, one of which (Type I) is thought to be caused by chronically low levels of gastric
acid and high levels of gastrin (hypergastrinemia), which ultimately induces morphologic changes in ECL cells.122 As seen below, high
gastrin levels, in certain circumstances, have also been implicated in the development of gastric adenocarcinoma.
PPIs
and gastric carcinoid tumors
A
hypergastrinemic state induces ECL cell changes, which are thought to progress through hyperplastic and dysplastic states
before finally becoming carcinoids. A dose-response relationship has been observed between the level of hypergastrinemia and
the severity of change in ECL cells.123,124,125 A recent study by Peghini et al observed that chronic hypergastrinemia alone in sporadic cases
of Zollinger-Ellison Syndrome (ZES) (without gastric atrophy or other risk factors) was associated with significant ECL changes,
with a highly significant direct correlation between fasting serum gastrin levels and ECL changes (r=0.62, p<0.00001).126 These and other findings
increasingly suggest that hypergastrinemia plays a central role in inducing ECL changes, which, in some cases, progress to
gastric carcinoid tumors. Although gastrin levels seen in ZES127 are generally higher than those seen with chronic PPI therapy,128 the presence of a dose-response
relationship in addition to the fact that, as seen below, H. pylori infection increases gastrin levels considerably
in PPI-treated patients, are causes for concern.
One
major cause of hypergastrinemia is long-term acid suppression.,. Chronic PPI therapy works by inducing profound acid suppression,
resulting in chronically high levels of gastrin. Therefore, it is biologically plausible that long-term PPI therapy could
lead to the development of gastric carcinoid tumors.
This
has been borne out in animal studies. The FDA approval documents for several PPIs demonstrate a possible association between
PPI use and gastric carcinoid development. In the Clinical Pharmacology review of Nexium in 2000 (referring to data for omeprazole),
a dose-response relationship was noted between omeprazole treatment and ECL cell hyperplasia and carcinoid development in
two two-year rat studies. The reviewer went on to state that ―due to genotoxic and tumorigenic potentials associated
with esomeprazole and/or omeprazole …, approval of esomeprazole for long term use is not recommended. …‖129 The Prevacid label
also includes a description of two two-year carcinogenicity studies in rats in which there was an increase in both ECL cell
hyperplasia and carcinoid incidence in a dose-response fashion.130
Of
particular concern is the fact that infection with H. pylori may further amplify the effects of PPI-induced hypergastrinemia.
H. pylori-induced gastritis leads to atrophy of the parietal glands in the oxyntic (acid-releasing) mucosa of the stomach,
a condition known as atrophic gastritis.131 This gastritis results in diminished gastric acid release (hypoacidity) and subsequent hypergastrinemia.
Through its own effects on gastrin, PPI therapy could amplify the effects of this H. pylori-induced hypergastrinemia,
triggering the growth of ECL cells and possibly leading to carcinoid development. Indeed, as can be seen in Table 1 (taken
from the approval documents for Protonix), in premarketing trials, there was a marked synergistic effect of H. pylori and
PPI therapy on gastrin levels, with the H. pylori-positive patients exhibiting a much higher dose-response increase
in gastrin levels compared with the H. pylori-negative patients.132
Table 1. Synergistic Effect of PPIs and H. pylori Infection on Serum Gastrin Levels [Taken from the Protonix
FDA approval documents].
STUDY
GMR-32022 (3001AI-300US)
MEDIUM
SERUM GASTRI LEVEL (pg/ml)
Tx Group |
H. |
Pylori |
Status [+] |
|
H. |
Pylori |
[-] |
Tx Group |
Median [n]
Basekube |
Median [n]
4-week |
Median [n]
8-week |
|
Median [n]
Basekube |
Median [n]
4-week |
Median [n]
8-week |
PL |
54[17] |
51[12] |
52[13] |
|
47[63 |
46[40] |
45.5[42] |
PANTO 10 mg |
56[30] |
59[19 |
64.5[16] |
|
48.5[140] |
53[94] |
52[61] |
PANTO 20 mg |
54[30] |
86.5[24] |
75[7] |
|
45.5[138] |
52[100] |
52.4[54] |
PANTO 40 mg |
61.5[42] |
126.5[30] |
284[5] |
|
49[126] |
66[93 |
64.5[30] |
|
|
|
|
|
|
|
|
PPIs
and gastric adenocarcinoma
In animals studies, high gastrin levels have also been associated with the development of gastric adenocarcinoma,
a more common and lethal133 variant of stomach cancer. Gastrin has a known trophic effect on the epithelial lining (mucosa) in the
stomach, stimulating cell growth.134 In animal studies, gastrin has been shown to be a significant factor in the development of carcinomas.135 Although a mechanism
has yet to be elucidated, it is concerning that there was an increased incidence of gastric intestinal metaplasia, a precursor
of gastric adenocarcinoma, in rats treated with lansoprazole, as acknowledged in the label.136 This association has also been suggested
in animal studies with transgenic mice designed to have chronically increased gastrin levels. These mice developed intestinal
metaplasia, dysplasia, and gastric adenocarcinoma at very high rates (75% with adenocarcinoma by 20 months of age). In addition,
the presence of Helicobacter infection in this murine model of gastric cancer was shown to result in accelerated
17
development
of adenocarcinoma.137 A potentially synergistic
effect of PPI therapy and Helicobacter infection on the risk for gastric carcinoma has been suggested in another animal
trial. Hagiwara et al found much higher rates of gastric adenocarcinoma in a group of Mongolian gerbils both infected with
H. pylori and on omeprazole (nine of 15 with adenocarcinoma) than in either the H. pylori-positive group (one
of 15) or the group on omeprazole alone (none of 15).138
PPIs
and gastric cancer: a plausible association?
Thus,
PPI therapy, by inducing chronically high levels of gastrin — especially in the presence of H. pylori infection
— can potentially lead to carcinoid tumors and, possibly, gastric adenocarcinoma. Widespread PPI use is a relatively
recent phenomenon and adequately powered, long-term follow-up studies do not yet exist to examine a potential association.
In other words, if there is a causal relationship between PPI use and gastric adenocarcinoma, there is likely a lengthy latency
period between PPI exposure and cancer development, possibly limiting the current availability of human data. However, a biologically
plausible mechanism, in addition to numerous animal studies, suggests a potential association between long-term PPI use and
cancer development in humans, and careful follow-up studies are needed.
H.
Overuse: inappropriate prescribing, unnecessarily high doses, empiric therapy, and inpatient initiation of PPI therapy
Use
of PPIs has grown almost exponentially over the past couple of decades due to their considerable effectiveness for certain
conditions, widespread inappropriate use for indications for which there is no evidence of benefit, and incorrectly perceived
lack of side effects. All of this is worsened by massive promotion of these products. A 2009 analysis using the National Ambulatory
Medical Care Survey found an increase in the frequency of prescription PPI treatment from less than five prescriptions per
1,000 GERD-related physician visits in 1995 to 43.9 prescriptions per 1,000 visits in 2006 in the U.S., a more than eight-fold
increase.139 In 2009, Nexium grossed the second
highest amount ($5 billion) in U.S. retail sales — and had the second highest number of prescriptions (26.5 million)
filled of all brand-name drugs.140 There were a
total of 119 million U.S. prescriptions filled in 2009 for all PPIs,141 totaling $13.6 billion in U.S. sales.142
However,
unnecessary and inappropriate use is widespread. Studies have estimated that potentially one-half to two-thirds of all patients
on PPIs do not have an appropriate indication.143,144 In
addition, many patients are using PPIs chronically, beyond the indicated time frame, for conditions such as GERD.145 Here we outline four key reasons for PPI overuse, followed
by recommendations to mitigate this extensive and dangerous problem.
(1)
Inappropriate prescribing
With
time, it has become clear that some serious side effects for PPIs do, in fact, exist and that there is considerable misprescribing
for indications for which PPIs have not been shown to be effective. However, many physicians have not changed their prescribing
habits in response to this new information. The lack of awareness about the increasing evidence of serious adverse effects
has allowed physician misprescribing and (for OTC versions of PPIs) patient
misuse, to continue. A recent study in Denmark involving 22 general practitioners and 42,634 patients found that 2.1% of all
patients were on long-term PPI treatment, but only 27% of these patients had verified indications for the therapy.146 The risk for dependence
with long-term use due to RAHS is a serious concern, especially in the 73% of patients for whom this therapy is considered
inappropriate. In 194 of the patients in the above study who lacked a verified indication, 119 (61%) had previously attempted
withdrawal unsuccessfully.147 A German study analyzing hospital discharge letters found that less than one-third of all patients with
a hospital discharge letter recommending a PPI had an evidence-based indication.148 In addition, in patients lacking a clear indication for
the PPI, there was no reason given for the recommendation in 37.8% of these patients.
(2)
Unnecessarily high doses
Another
problem, even in patients for whom PPIs are indicated, is using doses that are unnecessarily high. Many argue that high-dose
PPIs are neither necessary nor more effective than PPIs at low doses. In many cases, patients with common conditions such
as GERD may be justifiably stepped-down to lower doses without affecting the treatment course. In one study, 79% of patients
had no recurrence of heartburn or acid regurgitation six months after having been switched from multiple to single daily-dose
PPI therapy.149 As
seen in Table 2, a high proportion of patients with GERD achieve both short- and long-term symptom relief with lower PPI doses.
A recent systematic review concluded that ―… a substantial proportion (26-71%) of GERD patients can be adequately
managed with PPI treatment that is less intensive than that of continuous daily administration.‖150
In
addition to decreased daily doses, a number of randomized trials have shown that on-demand PPI therapy is sufficient to treat
symptoms of acid reflux, when compared to continuous therapy.151,152
For example, a Swiss study randomized patients with GERD who had
achieved remission of symptoms at four weeks on daily PPI to either on-demand or continued daily PPI treatment for maintenance.153 They found that patients
using PPIs on demand used 33% less medication and had only slightly lower rates of being heartburn free (80% vs. 86%, p<0.001)
but similar rates of satisfaction with treatment, epigastric pain, and regurgitation.
Thus,
taking lower or on-demand PPI doses may be just as effective for common conditions such as GERD, and could be key in helping
to prevent dose-dependent risks such as ECL cell hyperplasia or hip fracture, not to mention lowering costs.
(3)
Empiric PPI therapy for GERD
The
American Gastroenterological Association (AGA) released a review on the management of GERD based on an extensive review of
the literature in 2008 and noted that ―… the current consensus is that empirical PPI therapy is appropriate for
uncomplicated heartburn.‖154 This is consistent with the labeling for multiple PPIs that have listed as an indication the short-term
(four weeks) treatment of GERD. However, as the AGA noted in its review,155 reflux symptom resolution with empiric PPI therapy does
not necessarily represent a diagnosis of GERD. A systematic review of trials of empiric PPI therapy showed that a successful trial of a PPI is not a reliable
predictor of objective GERD.156 Specifically, successful
treatment with a PPI had a pooled sensitivity of only 78% and specificity of 54% when compared to abnormal 24-hour ambulatory
esophageal pH monitoring. A recent open-label study in Korean patients showed similar results, with only modest sensitivity
(77%) and specificity (56%) of empiric PPI therapy when compared with objective measures, including endoscopic findings of
erosive esophagitis or abnormal 48-hour esophageal pH monitoring for diagnosing GERD.157
This
poor specificity confirms that a large percentage of patients ―responding‖ to the PPI test do not in fact have
GERD. In a recent retrospective study, 200 patients with suspected GERD symptoms, half of whom were on a PPI, were placed
under pH monitoring while lying down.158 The key
finding was that in both patients on PPI therapy and those not on PPI therapy, the majority of the suspected GERD symptoms
were atypical (89% and 67%, respectively) and not related to actual acid reflux into the esophagus (90% and 86%, respectively).
Given
the propensity for a patient prescribed a PPI to remain on the drug in the long-term, the empiric treatment of many patients
who do not in fact have physiologic GERD is likely a major contributor to the overuse of, and damage from, PPIs.
(4)
Inpatient initiation of PPI therapy, often for stress ulcer prophylaxis
PPI
overuse by patients is compounded by physician overprescribing during inpatient hospital admissions and discharges. It has
been estimated that up to one-fourth of hospitalized patients outside of the intensive care unit (ICU) receive stress ulcer
prophylaxis despite a lack of evidence for its use in this setting.159 A retrospective chart review at the University of Florida Health Science Center found that 70% of patients admitted
to the general medicine service over a three-month period were started on acid-suppressive therapy (AST) in the hospital.
The most frequently prescribed ASTs were PPIs. Seventy-three percent of the AST prescriptions written at admission lacked
accepted indications, and in 49% of cases, no indication was found for initiating AST.160
When reported, the most common indication was for stress ulcer prophylaxis.
This
inappropriate inpatient use is often extended into the outpatient setting. For example, in the University of Florida study,
69% of the patients with inappropriate prescriptions continued that same treatment upon discharge.161 In another cost-analysis study, a 2.5 million member managed-care organization
(MCO) examined the records of patients who were initiated (no use 90 days prior to hospitalization) on PPI therapy during
an inpatient admission at a hospital and filled a prescription to resume that therapy within 30 days of discharge. Over 68%
of the individuals who filled PPI prescriptions after discharge lacked an appropriate indication, costing the MCO and the
patients an estimated $3,013,069 over the four-year course of the study.162 Yet another study showed that at three months after hospital discharge on inappropriate AST therapy,
80% of patients available for follow-up were still taking the drugs, and at six months, 50% of patients were still taking
these medications (all still without appropriate indications).163 21
Preventing
overuse and PPI alternatives
Reasonable
steps to mitigate PPI overuse in the inpatient setting
Significant
mitigation of PPI overuse can be accomplished in the inpatient (hospital) setting, beginning at admission. The unjustified
presence of a checkbox for GI prophylaxis on admission order sets has been shown to be an independent predictor of inappropriate
prescribing of PPIs in the inpatient setting.164 Therefore, a straightforward intervention to prevent this often automatic prescribing is to
remove PPIs from routine admission order sets, instead placing them only on those order sets where a PPI may be appropriate
(e.g., in an ICU setting).
Once
patients are admitted to the hospital, the implementation of clearer prescribing guidelines for PPIs could be instituted to
ensure more appropriate use. A study performed at Massachusetts General Hospital found significantly reduced rates of prescribing
of PPIs the month after guideline implementation compared to the retrospective analysis of the month before.165 Inpatient use dropped from 27% to
16% and prescriptions at discharge dropped from 16% to 10%. In the study, doctors were not bound to follow the rules but were
encouraged to use them as they felt appropriate. Clinical guidelines would probably most benefit less experienced, younger
doctors who, in other studies, have been noted to write a high percentage of inappropriate PPI prescriptions.166
In
another recent survey of internal medicine physicians and residents, predictors of ―low‖ PPI prescribing behavior
for general medicine patients (in most of whom a PPI would be unnecessary) were knowledge about stress-ulcer-prophylaxis indications
and concern about the side effects of PPI use.167 Thus, educational interventions could also be instituted to help mitigate this knowledge gap.
One hospital found that the implementation of didactic lectures for internal medicine residents on appropriate use of PPIs,
in addition to removing stress ulcer prophylaxis from the internal medicine admission checklist, reduced inappropriate prescribing
of PPIs both during hospitalization and after discharge.168
Finally,
an important intervention that has been shown to improve the accuracy of prescribing is the implementation of more rigorous
medication reconciliation procedures at discharge.169 If an individual has no indication for a prescription, it should not be issued.
Providers need to be alerted, either through a checkbox on the discharge form or through an electronic alert, to discontinue
PPIs when appropriate.
Measures
such as these would certainly help save costs and likely improve outcomes by reducing the widespread and unnecessary use of
PPIs in the hospital setting — use that all too often translates to long-term inappropriate therapy and preventable
adverse reactions after discharge.
Step-up
therapy with safer alternatives instead of starting with PPIs: a reasonable approach
Physicians
should encourage their patients to take a step-up approach in managing their reflux symptoms.170,171 Given the known adverse effects with long-term
PPI use, and the fact that empiric PPI therapy is inappropriately given as the first drug to be tried in so many patients
with no objective findings of acid reflux, step-up therapy, beginning with safer options, seems to be the most reasonable
approach. As Table 2 shows, a substantial number of patients suffering from GERD would benefit from these safer pharmacologic
approaches when used alone.
Moreover,
in related conditions such as dyspepsia, when these treatments are combined into a step-up approach (beginning with antacids,
progressing to H2As, and finally administering PPIs), an even larger number of patients have been shown to achieve long-term
relief of their symptoms. A large randomized, controlled trial conducted on 645 patients complaining of new-onset dyspepsia
in an outpatient setting found that a majority of patients (72%) achieved symptom relief at six months with step-up therapy,
similar to the rate seen with step-down therapy with PPIs first (70%) (OR 0.92; 95% CI 0.7–1.3).172 Not surprisingly, step-up therapy
also resulted in lower treatment costs over the six-month period.
Thus, step-up therapy has been shown to achieve similar rates of symptom relief as step-down therapy, with the potential
for lower costs and fewer serious adverse drug effects. Alternative pharmacologic therapies and lifestyle changes that could
comprise a comprehensive step-up approach for conditions like GERD and dyspepsia are outlined in the following section.
Table 2. Efficacy of Alternative (Other
Than Standard-Dose PPI) Pharmacologic Therapies for the Treatment of GERD.
1.
Antacid/Alginate category includes acid neutralizers (antacids), physical/mucosal barrier compounds (alginates, sucralfate,
etc.), or combination compounds.
2.
Obtained from independent review of randomized, controlled trials evaluating efficacy of alginate and antacid compounds compiled
in a review article (Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment
of heartburn and acid reflux. Aliment Pharmacol Ther. 2000 Jun;14[6]:669-90.) ―Short-term relief‖ for this category
included ―improved‖ or ―symptom-free‖ relief at four to eight weeks of treatment. All numbers are
absolute rates of symptom relief with each therapy, derived from randomized, controlled trials.
3.
Insufficient number or quality of trials evaluating long-term antacid/alginate efficacy.
4.
Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis.
Cochrane Database Syst Rev. 2007 Apr 18;(2):CD003244. ―Short-term relief‖ for this category includes ―relief
of symptoms‖ of ―reflux esophagitis‖ at four to 12 weeks of treatment. All numbers are absolute rates of
symptom relief with each therapy, derived from randomized, controlled trials.
5.
Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic
negative reflux disease. Cochrane Database Syst Rev. 2005 Apr
18;(2):CD003245.
―Long-term relief‖ defined as absence of significant symptoms (e.g., ―acid regurgitation,‖ ―heartburn,‖
or measurement of significant symptoms by GSRS scores) at 24-52 weeks of therapy. All numbers are absolute rates of symptom
relief with each therapy, derived from randomized, controlled trials.
6.
―Low-dose‖ PPI refers to a dose lower than (mostly half) the recommended dose listed in the label.
Components of step-up therapy
Lifestyle
modification
The
initial intervention in a step-up approach for reducing acid-related symptoms should be lifestyle modification. Although PPIs
can limit gastric acid secretion by reducing acidity, they cannot change the strength of the lower esophageal sphincter. Reflux
will still occur, but it might not feel as severe. By reducing food and liquid intake, altering body position (especially
during sleep), and taking other nonpharmacologic measures, one can limit the symptoms caused by acid reflux. In addition,
weight loss has been linked with a reduction in reflux symptoms.173
In one small study, 88% of obese patients on daily PPI therapy for
GERD symptoms were able to discontinue their PPI or take it less often after just one month of modifying their diets and achieving
substantial (average 17.5 lbs) weight loss.174 Before resorting to the extremes of PPI therapy, patients should try changing little things
in their everyday lives to achieve symptom relief.
Antacids and alginates
Should
lifestyle modifications fail to result in adequate relief, the use of antacids or an antacid/alginate combination is the next
step in this approach. In a 2007 study that included a meta-analysis of three randomized trials, alginate/antacid combinations
resulted in a clear improvement of reflux-related symptoms after two weeks compared to a placebo (26% absolute benefit over
placebo; 95% CI 12-41%).175 Although, in the same
study, another analysis of four randomized trials involving only antacids did not show a significant benefit over a placebo
in reducing symptoms after two to four weeks (absolute benefit over placebo 8%, p=0.06), two of the trials found that those
on antacids were less likely to have heartburn episodes requiring rescue antacids. Antacids, alginates, and physical/mucosal
barrier compounds are generally safe and without any major adverse effects, with the exception of aluminum-containing compounds
in those with renal insufficiency.176 As seen in
Table 2, a substantial number of patients with GERD would benefit from the use of these compounds alone. Therefore, this therapy
is a sufficient, and relatively safe, intervention for many people who would otherwise be placed unnecessarily on long-term
acid suppression.
H2As
If
antacids fail to yield sufficient relief, the next treatment option should be H2As, such as Tagamet. As noted in Table 2,
a Cochrane review of randomized, controlled trials of H2As for maintenance treatment of GERD showed that approximately half
(43-72%) of patients put on H2As achieved long-term symptom relief. In addition, H2As had significantly fewer side effects
than maintenance-dose (but not healing-dose) PPIs in head-to-head trials.177 Furthermore, when H2As are given as part of a comprehensive step-up approach, similar rates of symptom
resolution are seen compared with PPI therapy. In the randomized,
controlled trial of 645 patients with new-onset dyspepsia mentioned earlier, those randomized to a step-up approach (antacids-H2As-PPIs)
achieved similar rates of symptom resolution at six months (72%) as those given a step-down approach (PPIs initially).178 An important reason
to start with H2As as opposed to PPIs is the former‘s superior safety profile, as noted with several of the adverse
effects (e.g., CDI and clopidogrel interaction) mentioned in this petition. Thus, H2As, as part of a comprehensive step-up
therapeutic approach, achieve similar rates of symptom relief with less potential for some of the severe adverse effects associated
with PPI use, and would seem a reasonable alternative to empiric PPI therapy.
Low-dose
PPIs
As
seen in Table 2, should PPI use become necessary, providers can begin with a lower dose than commonly prescribed. Given the
large proportion of patients who achieve short (79%) and long-term (56-69%) symptomatic relief with these lower doses, and
the multiple adverse effects noted in this petition that occur in a dose-dependent fashion, this would seem to be the most
rational approach when initiating PPI therapy if the other step-up measures have not been effective.
Thus,
given the safer options that are available to patients with uncomplicated GERD or dyspepsia, it is concerning that step-down
therapy with PPIs is implied as an initial treatment option for these conditions on the PPI labels. As step-up therapy could
have a dramatic impact on the problem of unnecessary, and often dangerous, overuse of PPIs, it seems reasonable to educate
patients and providers alike on this alternative option for most of the circumstances in which PPIs are otherwise automatically
prescribed as first-choice treatments.
J.
Current labeling for PPIs is dangerously deficient
There
are seven different prescription PPI medications and three OTC PPI medications available on the U.S. market. The prescription
medications include Nexium, Dexilant, Prilosec, Zegerid, Prevacid, Protonix, and Aciphex. Another prescription drug, Vimovo,
is an arthritis medication that also contains omeprazole in order to function as an acid-suppressor. The OTC medications are
Prilosec OTC, Zegerid OTC, and Prevacid 24-Hr. The prescription medications have a variety of indications. The most prevalent
indications are treatment of GERD/erosive esophagitis, maintaining healed erosive esophagitis, H. pylori eradication
therapy, reducing NSAID-associated gastric ulcer, and treating pathological hypersecretory conditions (such as ZES). Treatment
periods vary depending on indication but will typically last from four to eight weeks with single daily doses.
No
prescription PPI has black box warnings on their labels for any side effect. Table 3 highlights the current labeling for the risk information being sought in this petition for both OTC and prescription
PPIs. At present, the OTC labels contain scant, if any, information regarding many of the risks listed in Table 3. In a 2000
joint meeting of the Nonprescription Drugs and Gastrointestinal Drugs advisory committees of the FDA, a panel voted 9-3 that
it was not certain consumers could take OTC omeprazole as directed without physician supervision.179 Despite the panel‘s findings,
omeprazole and lansoprazole have both been approved by the FDA for OTC use.
As
previously mentioned, the FDA has recently set a dangerous precedent in its move to eliminate a warning on fracture risk with
long-term PPI use from the labels of all OTC PPIs, based on the reasoning that since these drugs are only indicated for short-term
use, there is no need to disclose risks that are predominantly seen with longer-term use. This move was taken in spite of
the fact that the agency itself acknowledged that ―consumers … may take these products for periods of time that
exceed the directions on the OTC label.‖180 In addition, given that OTC PPIs are often considerably less expensive than their prescription
counterparts181,
some health plans and/or providers may actually encourage (and patients may themselves often opt for) the substitution of
OTC for prescription PPI formulations for long-term therapy of conditions such as GERD. Therefore, the decision to remove
the warning on fracture risk from OTC PPIs must be reversed, and the labels must be expanded to include all other dangerous
side effects outlined in this petition (e.g., magnesium deficiency). The precautionary principle requires that the FDA assume
that many patients do indeed take OTC medications long-term, therefore necessitating complete disclosure of risks with both
indicated (short-term) and off-label (long-term) use.
K.
Conclusion
PPIs are now one of the most widely used classes of prescription drugs, with an estimated one out of every 20 people
in the developed world currently taking the medications.182 Given that the majority of this use is probably inappropriate and with minimal
or no benefit to the patient, and that new, life-threatening risks with long-term therapy are continually emerging, it is
time for the medical community to re-evaluate the role of PPIs in everyday practice. As a critical first step, the FDA must
act immediately to require disclosure of the risk information outlined in the following recommendations to ensure that the
benefits of PPIs are appropriately balanced with their harms when doctors and patients make the decision on whether or not
to initiate therapy.
Table 3. Current Risk Information on PPI Labels for Adverse Reactions Being Sought in This Petition
XEROXED NEEDS TO BE ADDED HERE
All
information taken from most current label on either FDA or ―DailyMed‖ websites: Prilosec (05/2011), Nexium (05/2011),
Aciphex (05/2011), Dexilant (05/2011), Prevacid (06/2011), Protonix (05/2011), Zegerid (05/2011). 27
Prilosec
OTC (03/2007, and ―Dear Doctor‖ letters through 02/2011), Zegerid OTC (12/2009, and Letters through 12/2010),
Prevacid 24-Hr (08/2009, and Letters through 04/2011).
Risks
merely included within a list of potential adverse effects (such as in Postmarketing Experience or observations from
clinical trials) and where there was no specific warning devoted to that risk were not considered as a labeled adverse effect.
1.
On March 23, 2011, the FDA released an update of their March 25, 2010, Drug Safety Communication concerning fracture risk
with long-term PPI use. It stated that the warning present on all prescription PPIs (above) is not necessary on OTC PPIs due
to the fact that OTC PPIs come in lower doses and are only indicated for short-term use. (http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm).
2.
All risk information attributed to the Vimovo label is included in this table only if the risk is attributed to the omeprazole
(and not the NSAID) component in the label.
3.
Updated label not available on the FDA website for Nexium, and no Letter on the site concerning hypomagnesemia. A label ―revised‖
in May 2011 was found on the ―DailyMed‖ site but did not include hypomagnesemia. It is unclear whether the label
is out of date or whether Nexium was excluded from this classwide risk information for some reason. For all other PPIs, more
detailed risk information is found in the ―Warnings and Precautions,‖ ―Adverse Reactions,‖ and ―Patient
Information‖ sections.
4.
Provisionally. There are, so far, only letters from the FDA to manufacturers on the website recommending this change —
the updated labels are not up yet. (Letter dated December 20, 2010, for Zegerid OTC only includes warfarin and clopidogrel,
not cilostazol.)
5.
All PPIs (except Protonix and Prevacid) include a list of three examples in ―Highlights‖ of drugs affected by
gastric pH (ketoconazole, iron salts, digoxin). Zegerid, Dexilant, and Prilosec labels also include ampicillin esters in ―Highlights.‖
Protonix and Prevacid do not include any drugs as examples in the ―Highlights‖ section.
6.
The following information is in the Prevacid label (12.5 — ―Drug-drug Interactions‖): ―In an open-label,
single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5
to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and PREVACID 30 mg daily had
no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. While this study was not designed to assess the
safety of this combination of drugs, no major adverse reactions were noted.‖
II.
SUMMARY OF REQUESTED ACTIONS
1.
There should be a black box warning on all prescription PPIs and equivalent, prominent warnings on OTC PPIs, including information
about the following serious risks (there is currently no black box warning on PPIs for any side effect).
We
are suggesting the following wording:
-
Dependence on PPIs:
―Recent
evidence shows that treatment with proton pump inhibitors (PPIs) for as little as 4 weeks can cause patients to become dependent
on the medication, resulting in symptoms coming back after discontinuation of these drugs. This is caused by an increase in
the level of acid production in the stomach that occurs after stopping PPIs in what is known as ‗rebound acid hypersecretion‘
or RAHS. Prior to starting PPI therapy for symptoms such as heartburn or indigestion, talk to your doctor about alternative
therapies that may be safer. If therapy is needed, use should be limited to periods of 1-2 weeks or on-demand use. If you
feel that your heartburn or indigestion symptoms have worsened after finishing a trial of PPI therapy, do not restart the
medication before talking to your doctor.‖ In addition, given the serious
nature of the following adverse events, particularly in the elderly and other vulnerable populations, three other black box
(and OTC) warnings are necessary:
-
Bone Fracture: ―Long-term and multiple daily dose PPI therapy may be
associated
with an increased risk for osteoporosis-related fractures of the
hip,
wrist, or spine.‖ This is already in the ―Highlights‖ section but should be made a black box (and equivalent
OTC) warning due to the potential morbidity and mortality resulting from this adverse effect.
-
Infection: ―An increased likelihood of certain serious infections, such as C. difficile diarrhea and community-acquired
pneumonia, has been associated with long-term PPI use.‖ Pneumonia risk is currently entirely missing from all PPI labels,
while information on C. difficile infections — although attributed to all PPIs in the label — is,
for some reason, only present on three (Nexium, Prilosec, and Vimovo). Given the potentially fatal nature of these two conditions,
particularly in elderly and other vulnerable populations, both conditions need to be placed in a black box (and equivalent
OTC) warning.
-
Magnesium deficiency: ―Hypomagnesemia (magnesium deficiency), symptomatic and asymptomatic, has been reported
rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events
include tetany, heart arrhythmias, and seizures. In most patients, treatment of hypomagnesemia required magnesium replacement
and discontinuation of the PPI. For patients expected to be on prolonged treatment or who take PPIs with medications such
as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals should consider monitoring
magnesium levels prior to initiation of PPI treatment and periodically while the patient is on the drug.‖183
At
the FDA‘s behest, manufacturers recently placed warnings regarding the potential for hypomagnesemia in the ―Highlights‖
section of all prescription (but not OTC) PPI labels. However, due to the potentially fatal consequences of hypomagnesemia,
a more prominent black box warning is needed on all prescription PPIs. In addition, patients on OTC PPIs need to be made aware
of this adverse effect through an equivalent, prominent warning.
2.
A patient Medication Guide, approved by the FDA, should be required
for all prescription PPIs, to inform patients of the variety of serious risks now known to accompany the use of these drugs.
This should include the black box warnings previously mentioned and label changes mentioned below. In addition, the Medication
Guide should include detailed information on step-up therapy, including lifestyle changes, antacids, and H2As. There are currently
no Medication Guides for PPIs.
3.
The FDA should request that the sponsors of all prescription
PPI medications send a “Dear Doctor” letter to physicians and other providers that includes the black box
warnings mentioned earlier and the other label changes mentioned below. The letter should also include detailed information
on the efficacy and safety of step-up therapy, including lifestyle changes, antacids, and H2A therapy. Health care providers
should encourage their patients to take a step-up approach toward managing their acid-related symptoms. Lifestyle modifications
and dietary changes should be tried before resorting to medication. When appropriate, use of antacids and H2As should precede
PPI therapy. Only if these interventions prove ineffective should the patient then attempt treatment with PPIs. Finally, the
letter should include guidelines on appropriate prescribing of PPIs in the inpatient setting, including a reminder that PPI
therapy should be discontinued on discharge if not indicated.
4.
Other label changes
-
Drug-drug interaction: Taking PPIs may reduce the effectiveness of clopidogrel, leading to an increased rate of serious
adverse cardiovascular events, such as MI. Some PPIs (e.g., omeprazole) have been shown to have a higher likelihood of interaction
than others (e.g., pantoprazole), but multiple PPIs have been implicated. Although a version of this warning is already on
the omeprazole label, mention should be made in the ―Highlights‖ section of all PPI labels that the potential
for a classwide interaction cannot be ruled out at this time.
Appropriate
risk information on a potential interaction with at least two other medications used to treat serious conditions — methotrexate
and mycophenolate mofetil — also needs to be listed in the label.
-
Vitamin B12 deficiency: The available evidence on the potential for B12 deficiency with long-term PPI use needs to
be placed in the appropriate section of the label. The FDA has deemed the evidence sufficient to place a warning of the potential
for B12 deficiency on the Protonix label (under ―Warnings and Precautions‖). However, given the evidence presented
in this petition, and the fact that the warning attributes the potential risk to all ―acid-suppressing therapy‖
(not specifically to Protonix), this warning should be placed under ―Warnings and Precautions‖ in the labels of
all PPIs.
-
Acute interstitial nephritis: The available evidence regarding the potential for acute interstitial nephritis with
long-term PPI use, seen in at least 60 case reports, should be included in the appropriate section.
-
GERD-treatment length inconsistency for different PPIs: All PPIs approved for the treatment of GERD should have specific
recommendations for length of treatment beside all mentions of the indication in the label. Two PPIs do not currently have
specified lengths for GERD treatment on the ―Indications and Usage‖ sections of their labels. Aciphex includes
a ―4 week (with option for additional 4 weeks)‖ time frame only in the ―Dosage and Administration‖
section (2.3) but not in the ―Indications‖ section (1.3). The ―4 week‖ time frame should be included
in the ―Indications and Usage‖ section in the full prescribing information and in both ―Indications and
Usage‖ and ―Dosage and Administration‖ sections under ―Highlights,‖ on the Aciphex label. In
addition, Protonix does not include an indication subheading for (non-erosive)
GERD
in the ―Indications and Usage‖ section but does seem to include an indefinite indication for ―reduction
in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD‖ under another subheading in
this section (1.2). If Protonix is indeed indicated for non-erosive GERD, then we ask that this be displayed prominently in
the ―Indications‖ section under a separate subheading with a specific recommended time course (four to eight weeks
if appropriate).
III.
ENVIRONMENTAL IMPACT STATEMENT
Nothing
requested in this petition will have an impact on the environment.
IV.
CERTIFICATION
We
certify that, to the best of our knowledge and belief, this petition includes all information and views on which this petition
relies, and that it includes representative data and information known to the petitioners which are unfavorable to the petition.
Sincerely,
Eric
Nellis
Researcher
Public
Citizen‘s Health Research Group
Currently
at Georgetown University School of Medicine
Sammy
Almashat, M.D., M.P.H.
Staff
Researcher
Public
Citizen‘s Health Research Group
Helge
L. Waldum, M.D., PhD,
Professor
of Medicine and Head of Department of Digestive and Liver Diseases
Norwegian
National University of Science and Technology
Trondheim
University Hospital
Trondheim,
Norway
Michael
Carome, M.D.
Deputy
Director
Public
Citizen‘s Health Research Group
Sidney
M. Wolfe, M.D.
Director
Public Citizen‘s Health Research Group
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
1
IMS Health. Accessed on January 9, 2011. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Top%20Therapy%20Classes%20by%20U.S.RXs.pdf
2
Hussain S, Stefan M, Visintainer P, Rothberg M. Why do physicians prescribe stress ulcer prophylaxis to general medicine patients?
South Med J. 2010 Nov;103(11):1103-10.
3
Raghunath AS, O'Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther.
2005 Aug;22 Suppl 1:55-63.
4
Reimer C, Bytzer P. Clinical trial: long-term use of proton pump inhibitors in primary care patients - a cross sectional analysis
of 901 patients. Aliment Pharmacol Ther. 2009 Oct;30(7):725-32.
5
Donnellan C, Preston C, Moayyedi P, Sharma N. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic
negative reflux disease. Cochrane Database Syst Rev. 2004 Apr 18;(2):CD003245.
6
Cho YK, Choi MG, Lim CH, Nam KW, Chang JH, Park JM, Lee IS, Kim SW, Choi KY, Chung IS. Diagnostic value of the PPI test for
detection of GERD in Korean patients and factors associated with PPI responsiveness. Scand J Gastroenterol. 2010 May;45(5):533-9.
7
Soybel DI. Anatomy and physiology of the stomach. Surg Clin North Am. 2005 Oct;85(5):875-94.
8
Soybel DI. Anatomy and physiology of the stomach. Surg Clin North Am. 2005 Oct;85(5):875-94.
9
McColl KE, Gillen D. Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. Gastroenterology.
2009 Jul;137(1):20-2.
10
Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers
after withdrawal of therapy. Gastroenterology. 2009 Jul;137(1):80-7, 87.
11
Smith AD, Gillen D, Cochran KM, El-Omar E, McColl KE. Dyspepsia on withdrawal of ranitidine in previously asymptomatic volunteers.
Am J Gastroenterol. 1999 May;94(5):1209-13.
12
Fullarton GM, McLauchlan G, Macdonald A, Crean GP, McColl KE. Rebound nocturnal hypersecretion after four weeks treatment
with an H2 receptor antagonist. Gut. 1989 Apr;30(4):449-54.
13
Fullarton GM, Macdonald AM, McColl KE. Rebound hypersecretion after H2-antagonist withdrawal--a comparative study with nizatidine,
ranitidine and famotidine. Aliment Pharmacol Ther. 1991 Aug;5(4):391-8.
14
Smith AD, Gillen D, Cochran KM, El-Omar E, McColl KE. Dyspepsia on withdrawal of ranitidine in previously asymptomatic volunteers.
Am J Gastroenterol. 1999 May;94(5):1209-13.
15
el-Omar E, Banerjee S, Wirz A, Penman I, Ardill JE, McColl KE. Marked rebound acid hypersecretion after treatment with ranitidine.
Am J Gastroenterol. 1996 Feb;91(2):355-9.
16
Fullarton GM, Macdonald AM, McColl KE. Rebound hypersecretion after H2-antagonist withdrawal--a comparative study with nizatidine,
ranitidine and famotidine. Aliment Pharmacol Ther. 1991 Aug;5(4):391-8.
17
Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors
for the practising physician. Best Pract Res Clin Gastroenterol. 2001 Jun;15(3):355-70.
18
Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in
gastric acid secretory capacity after omeprazole treatment. Gut. 1996 Nov;39(5):649-53.
19
Gillen D, Wirz AA, McColl KE. Helicobacter pylori eradication releases prolonged
increased acid secretion following omeprazole treatment. Gastroenterology. 2004 Apr;126(4):980-8.
20
Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole—a gastric
proton pump inhibitor--on pentagastrin stimulated acid secretion in man. Gut. 1983 Apr;24(4):270-6.
21
Sharma B, Axelson M, Pounder RP, Lundborg P, Ohman M, Santana A, Talbot M, Cederberg C. Acid secretory capacity and plasma
gastrin concentration after administration of omeprazole to normal subjects. Aliment Pharmacol Ther. 1987 Feb;1(1):67-76.
22
Bell N, Karol MD, Sachs G, Greski-Rose P, Jennings DE, Hunt RH. Duration of effect of lansoprazole on gastric pH and acid
secretion in normal male volunteers. Aliment Pharmacol Ther. 2001 Jan;15(1):105-13.
23
Sharma BK, Walt RP, Pounder RE, Gomes MD, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24 hour decrease
of intragastric acidity. Gut. 1984 Sep;25(9):957-64.
24
Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and
its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology. 1999 Feb;116(2):239-47.
25
Gillen D, Wirz AA, McColl KE. Helicobacter pylori eradication releases prolonged
increased acid secretion following omeprazole treatment. Gastroenterology. 2004 Apr;126(4):980-8.
26
Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in
gastric acid secretory capacity after omeprazole treatment. Gut. 1996 Nov;39(5):649-53.
27
Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers
after withdrawal of therapy. Gastroenterology. 2009 Jul;137(1):80-7, 87.
28
Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers
after withdrawal of therapy. Gastroenterology. 2009 Jul;137(1):80-7, 87.
29
Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK. Rebound acid hypersecretion
from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol. 2010 Apr;45(4):389-94.
30
Sanduleanu S, Jonkers D, de Bruïne A, Hameeteman W, Stockbrügger RW. Changes in gastric mucosa and luminal environment during
acid-suppressive therapy: a review in depth. Dig Liver Dis. 2001 Nov;33(8):707-19.
31
Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in
gastric acid secretory capacity after omeprazole treatment. Gut. 1996 Nov;39(5):649-53.
32
Qvigstad G, Arnestad JS, Brenna E, Waldum HL. Treatment with proton pump inhibitors induces
tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients. Scand J Gastroenterol. 1998
Dec;33(12):1244-8.
33
Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and
its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology. 1999 Feb;116(2):239-47.
34
Niklasson A, Lindström L, Simrén M, Lindberg G, Björnsson E. Dyspeptic symptom development after discontinuation of a proton
pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol. 2010 Jul;105(7):1531-7.
35
Björnsson E, Abrahamsson H, Simrén M, Mattsson N, Jensen C, Agerforz P, Kilander A. Discontinuation of proton pump inhibitors
in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006 Sep 15;24(6):945-54.
36
McColl KE, Gillen D. Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. Gastroenterology. 2009 Jul;137(1):20-2.
37
Van Soest EM, Siersema PD, Dieleman JP, Sturkenboom MC, Kuipers EJ. Persistence and adherence
to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther. 2006 Jul 15;24(2):377-85.
38
McColl KE, Gillen D. Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. Gastroenterology.
2009 Jul;137(1):20-2.
39
FDA. (2010 May 25) FDA Drug Safety Communication: possible increased risk of fractures of the hip, wrist, and spine with the
use of proton pump inhibitors. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm213206.htm. Accessed on December 16, 2010.
40
Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z. Proton pump inhibitor use, hip fracture, and change
in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2010 May 10;170(9):765-71.
41
Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006 Dec 27;296(24):2947-53.
42
Cardinal L, Shankar U, Sharma S, Masood W. Systematic review and synthesis: proton pump inhibitor exposure duration and association
with hip fracture. Am J Gastroenterol. 2010; 105:S29-30 (Abstract).
43
Ditah I, Kutait A, Janarthanan S, Msallaty Z, Tageja N, Kingah P, Luma H, May E. Do proton pump inhibitors increase the risk
of bone fractures? a meta-analysis of 14 observational studies. Am J Gastroenterol. 2010; 105:S40-41 (Abstract).
44
Bo-Linn GW, Davis GR, Buddrus DJ, Morawski SG, Santa Ana C, Fordtran JS. An evaluation
of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest. 1984 Mar;73(3):640-7.
45
Graziani G, Como G, Badalamenti S, Finazzi S, Malesci A, Gallieni M, Brancaccio D, Ponticelli C. Effect of gastric acid secretion
on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant. 1995;10(8):1376-80.
46
Serfaty-Lacrosniere C, Wood RJ, Voytko D, Saltzman JR, Pedrosa M, Sepe TE, Russell RR. Hypochlorhydria from short-term omeprazole
treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll
Nutr. 1995 Aug;14(4):364-8.
47
O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption
in women: a randomized crossover trial. Am J Med. 2005 Jul;118(7):778-81.
48
Faulhaber GA,
Furlanetto TW.
Could magnesium depletion play a role on fracture risk in PPI users? Arch
Intern Med. 2010 Oct 25;170(19):1776.
49
National Institutes of Health, Office of Dietary Supplements. Dietary Supplement Fact Sheet: Magnesium. http://ods.od.nih.gov/factsheets/magnesium/. Accessed on July 7, 2011.
50
Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone
mineral density loss. Gastroenterology. 2010 Mar;138(3):896-904. 33
51 Roblin X, Phelip JM. Biological plausibility between proton pump inhibitory therapy and hip fracture:
hyperhomocysteinemia can be the link. Am J Gastroenterol. 2009 Apr;104(4):1052.
52
Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med.
2011 Feb 14. [Epub ahead of print]
53
FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump
inhibitors (Update). http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm213206.htm. Accessed on June 8, 2011.
54
FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump
inhibitors (Update). http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm213206.htm. Accessed on June 8, 2011.
55
Consumer Reports. ―Over-the-counter heartburn drug could save consumers thousands.‖
Accessed on June 15, 2011. http://www.consumerreports.org/health/prescription-drugs/over-the-counter-heartburn-drug-could-save-consumers-thousands-1-07/overview/0107_over-the-counter_heartburn_drug_could_save_consumers_thousands.htm
56
Compare D, Pica L, Rocco A, De Giorgi F, Cuomo R, Sarnelli G, Romano M, Nardone G. Effects of long-term PPI treatment on producing
bowel symptoms and SIBO. Eur J Clin Invest. 2011;41(4):380-6.
57
Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, Duroux P, Nicolet M, Pignatelli B, Blum AL, Gonvers JJ, Fried
M. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study.
Gut. 1996 Jul;39(1):54-9.
58
Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump
inhibitor therapy. Clin Gastroenterol Hepatol. 2010 Jun;8(6):504-8.
59
Hussain S, Stefan M, Visintainer P, Rothberg M. Why do physicians prescribe stress ulcer prophylaxis to general medicine patients?
South Med J. 2010 Nov;103(11):1103-10.
60
Gurian L, Ward TT, Katon RM. Possible foodborne transmission in a case of pseudomembranous
colitis due to Clostridium difficile: influence of gastrointestinal secretions on Clostridium difficile infection.
Gastroenterology. 1982 Aug;83(2):465-9.
61
Jayatilaka S, Shakov R, Eddi R, Bakaj G, Baddoura WJ, DeBari VA. Clostridium difficile
infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with
the use of proton pump inhibitors. Ann Clin Lab Sci. 2007 Summer;37(3):241-7.
62
Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, Talmor D. Iatrogenic
gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010 May 10;170(9):784-90.
63
Haider F, Raza N, Komar M, Inverso N, Rahman O, Prall S, Sartorius J, Esolen L, Shepperson
S. Proton pump inhibitor use predicts severity of Clostridium difficile infection. Am J Gastroenterol. 2010; 105:S409
(Abstract).
64
Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for
recurrent Clostridium difficile infection. Arch Intern Med. 2010 May 10;170(9):772-8.
65
Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review
and meta-analysis. CMAJ. 2011 Feb 22;183(3):310-9.
66
Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of
gastric acid-suppressive drugs. JAMA. 2004 Oct 27;292(16):1955-60.
67
Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired
pneumonia: a population-based case-control study. Arch Intern Med. 2007 May 14;167(9):950-5.
68
Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review
and meta-analysis of clinical trials. Can J Gastroenterol. 2008 Sep;22(9):761-6.
69
Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C, D'Amico D, Hamelin B. The new proton pump inhibitor esomeprazole
is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind,
placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther. 2001 Jul;15(7):927-35.
70
Eurich DT, Sadowski CA, Simpson SH, Marrie TJ, Majumdar SR. Recurrent community-acquired pneumonia in patients starting acid-suppressing
drugs. Am J Med. 2010 Jan;123(1):47-53. 71 Rodríguez LA, Ruigómez A, Wallander MA, Johansson S. Acid-suppressive drugs and
community-acquired pneumonia. Epidemiology. 2009 Nov;20(6):800-6.
72
Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review
and meta-analysis. CMAJ. 2011 Feb 22;183(3):310-9.
73
Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol. 2011 Mar;27(2):180-5.
74
FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).
http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm. Accessed on March 3, 2011.
75
Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006 Oct 26;355(17):1834-6.
76
Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol. 2010 Sep 20. 2011 Mar;27(2):180-5.
77
Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol. 2011 Mar;27(2):180-5.
78
Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol. 2011 Mar;27(2):180-5.
79
Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. Q J Med. 2010 Jun;103(6):387-95.
80
Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol. 2011 Mar;27(2):180-5.
81
FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs).
http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm. Accessed on March 3, 2011.
82
Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy
SA, Cannon CP; the COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med.
2010 Nov 11;363(20):1909-1917.
83
Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW,
Quigley EM, Scheiman J, Sperling LS, Tomaselli GF; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant
use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on
reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010 Dec;105(12):2533-49.
84
Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW,
Quigley EM, Scheiman J, Sperling LS, Tomaselli GF; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant
use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on
reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010 Dec;105(12):2533-49.
85
Alkhatib AA, Elkhatib FA, Khatib OF. Gastric acid-reducing medications and clopidogrel: what are the latest FDA recommendations?
Am J Gastroenterol. 2010 May;105(5):1211.
86
Siriswangvat S, Sansanayudh N, Nathisuwan S, Panomvana D. Comparison between the effect of omeprazole and rabeprazole on the
antiplatelet action of clopidogrel. Circ J. 2010 Oct;74(10):2187-92.
87
Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. The influence
of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests. J Cardiovasc
Pharmacol. 2010 Nov;56(5):532-9.
88
Stockl KM, Le L, Zakharyan A, Harada AS, Solow BK, Addiego JE, Ramsey S. Risk of rehospitalization for patients using clopidogrel
with a proton pump inhibitor. Arch Intern Med. 2010 Apr 26;170(8):704-10.
89
Charlot M, Ahlehoff O, Norgaard ML, Jørgensen CH, Sørensen R, Abildstrøm SZ, Hansen PR, Madsen JK, Køber L, Torp-Pedersen
C, Gislason G. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a
nationwide cohort study. Ann Intern Med. 2010 Sep 21;153(6):378-86.
90
Valkhoff VE, 't Jong GW, Van Soest EM, Kuipers EJ, Sturkenboom MC. Risk of recurrent myocardial infarction with the concomitant
use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther. 2011 Jan;33(1):77-88.
91
Tsai YW, Wen YW, Huang WF, Chen PF, Kuo KN, Hsiao FY. Cardiovascular and gastrointestinal events of three antiplatelet therapies:
clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal
bleeding. J Gastroenterol. 2011 Jan;46(1):39-45.
92
Kreutz RP, Stanek EJ, Aubert R, Yao J, Breall JA, Desta Z, Skaar TC, Teagarden JR, Frueh FW, Epstein RS, Flockhart DA. Impact
of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel medco outcomes
study. Pharmacotherapy. 2010 Aug;30(8):787-96.
93
Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy
SA, Cannon CP; the COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med.
2010 Nov 11;363(20):1909-1917.
94
Southworth MR, Temple R. Interaction of clopidogrel and omeprazole. N Engl J Med. 2010 Nov 11;363(20):1977.
95
Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton
pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005 Jun;20(3):153-67.
96
Huang CC, Chen YC, Leu HB, Chen TJ, Lin SJ, Chan WL, Chen JW. Risk of adverse outcomes in Taiwan associated with concomitant
use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol. 2010
Jun 15;105(12):1705-9.
97
AstraZeneca Pharmaceuticals LP. Prilosec label. Revised January 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019810s092,022056s008lbl.pdf. Accessed on April 23, 2011.
98
Fontes-Carvalho R, Albuquerque A, Araújo C, Pimentel-Nunes P, Ribeiro VG. Omeprazole, but not pantoprazole, reduces the antiplatelet
effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs
drug interaction. Eur J Gastroenterol Hepatol. 2011 May;23(5):396-404.
99
Siriswangvat S, Sansanayudh N, Nathisuwan S, Panomvana D. Comparison between the effect of omeprazole and rabeprazole on the
antiplatelet action of clopidogrel. Circ J. 2010 Oct;74(10):2187-92.
100
Kreutz RP, Stanek EJ, Aubert R, Yao J, Breall JA, Desta Z, Skaar TC, Teagarden JR, Frueh FW, Epstein RS, Flockhart DA. Impact
of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel medco outcomes
study. Pharmacotherapy. 2010 Aug;30(8):787-96.
101
Stockl KM, Le L, Zakharyan A, Harada AS, Solow BK, Addiego JE, Ramsey S. Risk of rehospitalization for patients using clopidogrel
with a proton pump inhibitor. Arch Intern Med. 2010 Apr 26;170(8):704-10.
102
Siriswangvat S, Sansanayudh N, Nathisuwan S, Panomvana D. Comparison between the effect of omeprazole and rabeprazole on the
antiplatelet action of clopidogrel. Circ J. 2010 Oct;74(10):2187-92.
103
Kreutz RP, Stanek EJ, Aubert R, Yao J, Breall JA, Desta Z, Skaar TC, Teagarden JR, Frueh FW, Epstein RS, Flockhart DA. Impact
of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel medco outcomes
study. Pharmacotherapy. 2010 Aug;30(8):787-96.
104
AstraZeneca Pharmaceuticals LP. Nexium label. Revised August 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021153s036,021957s009,022101s006lbl.pdf. Accessed on January 9, 2011.
105
Doesch AO, Mueller S, Konstandin M, Celik S, Erbel C, Kristen A, Frankenstein L, Koch A, Ehlermann P, Zugck C, Katus HA. Proton
pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil.
Transplant Proc. 2010 Dec;42(10):4243-6.
106
Kofler S, Deutsch MA, Bigdeli AK, Shvets N, Vogeser M, Mueller TH, Meiser B, Steinbeck G, Reichart B, Kaczmarek I. Proton
pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant.
2009 Jun;28(6):605-11.
107
Kofler S, Wolf C, Shvets N, Sisic Z, Müller T, Behr J, Sohn HY, Vogeser M, Shipkova M, Meiser B, Steinbeck G, Reichart B,
Kaczmarek I. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant
recipients. J Heart Lung Transplant. 2011 May;30(5):565-71.
108
Santucci R, Leveque D, Lescoute A, Kemmel V, Herbrecht R. Delayed elimination of methotrexate associated with co-administration
of proton pump inhibitors. Anticancer Res. 2010 Sep;30(9):3807-10.
109
Joerger M, Huitema AD, van den Bongard HJ, Baas P, Schornagel JH, Schellens JH, Beijnen JH. Determinants of the elimination
of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol.
2006 Jul;62(1):71-80.
110
Santucci R, Leveque D, Lescoute A, Kemmel V, Herbrecht R. Delayed elimination of methotrexate associated with co-administration
of proton pump inhibitors. Anticancer Res. 2010 Sep;30(9):3807-10.
111
den Elzen WP, Groeneveld Y, de Ruijter W, Souverijn JH, le Cessie S, Assendelft WJ, Gussekloo J. Long-term use of proton pump
inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther. 2008 Mar 15;27(6):491-7.
112
Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin
B12 deficiency in older adults. J Clin Epidemiol. 2004 Apr;57(4):422-8.
113
Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. Do acid-lowering agents affect vitamin B12 status in older
adults? J Am Med Dir Assoc. 2008 Mar;9(3):162-7.
114
Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. Do acid-lowering agents affect vitamin B12 status in older
adults? J Am Med Dir Assoc. 2008 Mar;9(3):162-7.
115
Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin
B12 deficiency in older adults. J Clin Epidemiol. 2004 Apr;57(4):422-8.
116
Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. Do acid-lowering agents affect vitamin B12 status in older
adults? J Am Med Dir Assoc. 2008 Mar;9(3):162-7.
117
den Elzen WP, Groeneveld Y, de Ruijter W, Souverijn JH, le Cessie S, Assendelft WJ, Gussekloo J. Long-term use of proton pump
inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther. 2008 Mar 15;27(6):491-7.
118
Sierra F, Suarez M, Rey M, Vela MF. Systematic review: Proton pump inhibitor-associated
acute interstitial nephritis. Aliment Pharmacol Ther. 2007 Aug 15;26(4):545-53.
119
The American Cancer Society. Stomach cancer: 5-year survival statistics by stage. http://www.cancer.org/cancer/stomachcancer/detailedguide/stomach-cancer-survival-rates. Accessed on January 9, 2011.
120
The American Cancer Society. Gastrointestinal carcinoid tumors: 5-year survival statistics by stage. http://www.cancer.org/Cancer/GastrointestinalCarcinoidTumor/DetailedGuide/gastrointestinal-carcinoid-tumors-survival-rates. Accessed on April 30, 2011.
121
Kamanger F, Dawsey SM, Blaser MJ, Perez-Perez GI, Pietinen P, Newschaffer CJ, Abnet CC,
Albanes D, Virtamo J, Taylor PR. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter
pylori seropositivity. JNatl Cancer Inst. 2006 Oct 18;98(20):1445-52.
122
Burkitt MD, Pritchard DM. Review article: Pathogenesis and management of gastric carcinoid tumours.
Aliment
Pharmacol Ther. 2006 Nov 1;24(9):1305-20.
123
Borch K, Renvall H, Liedberg G, Andersen BN. Relations between circulating gastrin and endocrine cell proliferation in the
atrophic gastric fundic mucosa. Scand J Gastroenterol. 1986 Apr;21(3):357-63.
124
Delle Fave G, Marignani M, Moretti A, D'Ambra G, Martino G, Annibale B. Hypergastrinemia and enterochromaffin-like cell hyperplasia.
Yale J Biol Med. 1998 May-Aug;71(3-4):291-301.
125
Peghini PL, Annibale B, Azzoni C, Milione M, Corleto VD, Gibril F, Venzon DJ, Delle Fave G, Bordi C, Jensen RT. Effect of
chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology.
2002 Jul;123(1):68-85.
126
Peghini PL, Annibale B, Azzoni C, Milione M, Corleto VD, Gibril F, Venzon DJ, Delle Fave G, Bordi C, Jensen RT. Effect of
chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology.
2002 Jul;123(1):68-85.
127
Peghini PL, Annibale B, Azzoni C, Milione M, Corleto VD, Gibril F, Venzon DJ, Delle Fave G, Bordi C, Jensen RT. Effect of
chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology.
2002 Jul;123(1):68-85.
128
Food and Drug Administration. Drug Approval Package. Protonix. Medical Review Part 3. [p.15-16 pdf] http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_medr_P3.pdf. Accessed on January 9, 2011.
129
Food and Drug Administration. Pharmacology Review - Nexium. 2000. p 63. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21154_Nexium_pharmr.pdf. Accessed on January 9, 2011.
130
Takeda Pharmaceuticals America, Inc. Revised August 2010. Prevacid label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020406s074,021428s021lbl.pdf. Accessed on January 9, 2011.
131
Kuipers EJ. Review article: Relationship between Helicobacter pylori, atrophic
gastritis and gastric cancer. Aliment Pharmacol Ther. 1998 Feb;12 Suppl 1:25-36.
132
Food and Drug Administration. Drug Approval Package. Protonix. Medical Review Part 3. [p.15-16 pdf] http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_medr_P3.pdf. Accessed on January 9, 2011.
133
The American Cancer Society. Stomach cancer: 5-year survival statistics by stage. http://www.cancer.org/cancer/stomachcancer/detailedguide/stomach-cancer-survival-rates. Accessed on January 9, 2011.
134
Orlando LA, Lenard L, Orlando RC. Chronic hypergastrinemia: causes and consequences. Dig Dis Sci. 2007 Oct;52(10):2482-9.
135
Wang TC, Dangler CA, Chen D, Goldenring JR, Koh T, Raychowdhury R, Coffey RJ, Ito S,
Varro A, Dockray GJ, Fox JG. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse
model of gastric cancer. Gastroenterology. 2000 Jan;118(1):36-47.
136
Takeda Pharmaceuticals America, Inc. Revised August 2010. Prevacid label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020406s074,021428s021lbl.pdf. Accessed April 30, 2011.
137
Wang TC, Dangler CA, Chen D, Goldenring JR, Koh T, Raychowdhury R, Coffey RJ, Ito S,
Varro A, Dockray GJ, Fox JG. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse
model of gastric cancer. Gastroenterology. 2000 Jan;118(1):36-47.
138
Hagiwara T, Mukaisho K, Nakayama T, Sugihara H, Hattori T. Long-term proton pump inhibitor
administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with
Helicobacter pylori. Gut. 2011 May;60(5):624-30.
139
Friedenberg FK, Hanlon A, Vanar V, Nehemia D, Mekapati J, Nelson DB, Richter JE. Trends in gastroesophageal reflux disease
as measured by the National Ambulatory Medical Care Survey. Dig Dis Sci. 2010 Jul;55(7):1911-7.
140
Drug Topics: The Newsmagazine for Pharmacists. (2010 Jun 17) 2009 Top Branded Drugs by Retail Dollars and 2009 Top Branded
Drugs by Total Prescriptions. http://drugtopics.modernmedicine.com/drugtopics. Accessed on April 30, 2011.
141
IMS Health. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Top%20Therapy%20Classes%20by%20U.S.RXs.pdf. Accessed on April 30, 2011.
142
IMS Health. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Top%20Therapy%20Classes%20by%20U.S.Sales.pdf. Accessed on April 30, 2011.
143
Reimer C, Bytzer P. Clinical trial: long-term use of proton pump inhibitors in primary care patients - a cross sectional analysis
of 901 patients. Aliment Pharmacol Ther. 2009 Oct;30(7):725-32.
144
Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recommendations for PPI in hospital
discharge letters. Eur J Clin Pharmacol. 2010 Dec;66(12):1265-71.
145
Raghunath AS, O'Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther.
2005 Aug;22 Suppl 1:55-63.
146
Reimer C, Bytzer P. Clinical trial: long-term use of proton pump inhibitors in primary care patients - a cross sectional analysis
of 901 patients. Aliment Pharmacol Ther. 2009 Oct;30(7):725-32.
147
Reimer C, Bytzer P. Clinical trial: long-term use of proton pump inhibitors in primary care patients - a cross sectional analysis
of 901 patients. Aliment Pharmacol Ther. 2009 Oct;30(7):725-32.
148
Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recommendations for PPI in hospital
discharge letters. Eur J Clin Pharmacol. 2010 Dec;66(12):1265-1271.
149
Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective
study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol. 2003 Sep;98(9):1940-4.
150
Lee TJ, Fennerty MB, Howden CW. Systematic review: Is there excessive use of proton pump inhibitors in gastro-oesophageal
reflux disease? Aliment Pharmacol Ther. 2004 Dec;20(11-12):1241-51.
151
Kao AW, Sheu BS, Sheu MJ, Chang YM, Huang SF, Chuang CH, Lai YL, Kao YH. On-demand therapy for Los Angeles grade A and B reflux
esophagitis: esomeprazole versus omeprazole. J Formos Med Assoc. 2003 Sep;102(9):607-12.
152
Meineche-Schmidt W, Hvengaard A, Juhl HH. The economical impact of six months management of gastroesophageal reflux disease
in primary care: comparison between on-demand treatment and treatment courses with esomeprazole. Gastroenterology 2004; 126:
A-338 (Abstract).
153
Szucs T, Thalmann C, Michetti P, Beglinger C. Cost analysis of long-term treatment of patients with symptomatic gastroesophageal
reflux disease (GERD) with esomeprazole on-demand treatment or esomeprazole
continuous
treatment: an open, randomized, multicenter study in Switzerland. Value Health. 2009 Mar-Apr;12(2):273-81.
154
Kahrilas PJ, Shaheen NJ, Vaezi MF; American Gastroenterological Association Institute; Clinical Practice and Quality Management
Committee. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux
disease. Gastroenterology. 2008 Oct;135(4):1392-1413, 1413.
155
Kahrilas PJ, Shaheen NJ, Vaezi MF; American Gastroenterological Association Institute; Clinical Practice and Quality Management
Committee. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux
disease. Gastroenterology. 2008 Oct;135(4):1392-1413, 1413.
156
Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux
disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004 Apr 6;140(7):518-27.
157
Cho YK, Choi MG, Lim CH, Nam KW, Chang JH, Park JM, Lee IS, Kim SW, Choi KY, Chung IS. Diagnostic value of the PPI test for
detection of GERD in Korean patients and factors associated with PPI responsiveness. Scand J Gastroenterol. 2010 May;45(5):533-9.
158
Aravapalli A, Arevalo L, Pohl D, Castell D. PPI Therapy has little effect on suspected
GERD related symptoms in the recumbent position. Am J Gastroenterol 2010; 105:S1–S571; doi:10.1038/ajg.2010.320 (Abstract).
159
Hussain S, Stefan M, Visintainer P, Rothberg M. Why do physicians prescribe stress ulcer prophylaxis to general medicine patients?
South Med J. 2010 Nov;103(11):1103-10.
160
Gupta R, Garg P, Kottoor R, Munoz JC, Jamal MM, Lambiase LR, Vega KJ. Overuse of acid suppression therapy in hospitalized
patients. South Med J. 2010 Mar;103(3):207-11.
161
Gupta R, Garg P, Kottoor R, Munoz JC, Jamal MM, Lambiase LR, Vega KJ. Overuse of acid suppression therapy in hospitalized
patients. South Med J. 2010 Mar;103(3):207-11.
162
Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient
initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large
managed care organization. J Manag Care Pharm. 2010 Mar;16(2):122-9.
163
Zink DA, Pohlman M, Barnes M, Cannon ME. Long-term use of acid suppression started inappropriately during hospitalization.
Aliment Pharmacol Ther. 2005 May 15;21(10):1203-9.
164
Eid SM, Boueiz A, Paranji S, Mativo C, Landis R, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among
academic and non-academic hospitalists. Intern Med. 2010;49:2561-8.
165
Yachimski PS, Farrell EA, Hunt DP, Reid AE. Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract
bleeding: effect of standardized guidelines on prescribing practice. Arch Intern Med. 2010 May 10;170(9):779-83.
166
Craig DG, Thimappa R, Anand V, Sebastian S. Inappropriate utilization of intravenous proton pump inhibitors in hospital practice--a
prospective study of the extent of the problem and predictive factors. Q J Med. 2010 May;103(5):327-35.
167
Hussain S, Stefan M, Visintainer P, Rothberg M. Why do physicians prescribe stress ulcer prophylaxis to general medicine patients?
South Med J. 2010 Nov;103(11):1103-10.
168
Grigg E, Davis I, Williams D, Schade R. Can intervention reduce abuse of proton pump inhibitors? Am J Gastroenterol 2010;
105:S404 (Abstract).
169
Murphy EM, Oxencis CJ, Klauck JA, Meyer DA, Zimmerman JM. Medication reconciliation at an academic medical center: implementation
of a comprehensive program from admission to discharge.
Am
J Health Syst Pharm. 2009 Dec 1;66(23):2126-31.
170
Ford AC, Moayyedi P. Should we step-up or step-down in the treatment of new-onset dyspepsia in primary care? Pol Arch Med
Wewn. 2009 Jun;119(6):391-6.
171
van Marrewijk CJ, Mujakovic S, Fransen GA, Numans ME, de Wit NJ, Muris JW, van Oijen MG, Jansen JB, Grobbee DE, Knottnerus
JA, Laheij RJ. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists,
and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled
trial. Lancet. 2009 Jan 17;373:215-25.
172
van Marrewijk CJ, Mujakovic S, Fransen GA, Numans ME, de Wit NJ, Muris JW, van Oijen MG, Jansen JB, Grobbee DE, Knottnerus
JA, Laheij RJ. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists,
and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled
trial. Lancet. 2009 Jan 17;373:215-25.
173
Mathus-Vliegen EM, Tygat GN. Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic
gastric balloon distension. Scand J Gastroenterol. 2002 Nov;37(11):1246-52.
174
Sprung D, Sprung D. Is weight reduction the key factor in controlling GERD symptoms in obese patients? Am J Gastroenterol
2010; 105:S27; doi:10.1038/ajg.2010.320 (Abstract).
175
Tran T, Lowry AM, El-Serag HB. Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease therapies.
Aliment Pharmacol Ther. 2007 Jan 15;25(2):143-53.
176
Marks IN. Sucralfate--safety and side effects. Scand J Gastroenterol Suppl. 1991;185:36-42.
177
Donnellan C, , Preston C, Moayyedi P, Sharma N. Medical treatments for the maintenance therapy of reflux oesophagitis and
endoscopic negative reflux disease. Cochrane Database Syst Rev. 2004 Apr 18;(2):CD003245.
178
van Marrewijk CJ, Mujakovic S, Fransen GA, Numans ME, de Wit NJ, Muris JW, van Oijen MG, Jansen JB, Grobbee DE, Knottnerus
JA, Laheij RJ. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists,
and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled
trial. Lancet. 2009 Jan 17;373(9659):215-25.
179
Gottlieb S. FDA panel advises against omeprazole as over the counter drug. BMJ. 2000 Nov 4;321(7269):1099.
180
FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump
inhibitors (Update). http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm213206.htm. Accessed on June 8, 2011.
181
Consumer Reports. ―Over-the-counter heartburn drug could save consumers thousands.‖
Accessed on June 15, 2011. http://www.consumerreports.org/health/prescription-drugs/over-the-counter-heartburn-drug-could-save-consumers-thousands-1-07/overview/0107_over-the-counter_heartburn_drug_could_save_consumers_thousands.htm
182
McColl KE, Gillen D. Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. Gastroenterology.
2009 Jul;137(1):20-2.
183 Language taken almost
verbatim from the current label (Section 5.7 under Warnings and Precautions). Eisai Co., Ltd., Tokyo, Japan. Revised
May 2011. Aciphex Label. Web. Accessed on June 15, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020973s028lbl.pdf.